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ABSTRACT 
 
CD9, a member of the tetraspanin superfamily of cell surface proteins, is 
expressed on a wide variety of cells where it participates in the regulation of cell adhesive 
functions. Despite numerous reports of CD9 effects on cell migration, the molecular 
mechanisms governing CD9 promoted cell migration are as yet unclear. Earlier studies 
have shown that expression of human CD9 in Chinese hamster ovary (CHO) cells caused 
increased cell migration to the extracellular matrix (ECM) protein fibronectin (FN) when 
compared to Mock control cells. The goal of this study was to determine the molecular 
basis for CD9 mediated cell motility to FN. 
Using CHO cells as a model system, and pharmacological inhibitors of crucial 
signaling pathways known to participate in the signaling events that regulate cell motility, 
we investigated the mechanism driving CD9 enhanced cell motility. Our findings show 
that the phosphatidylinositol-3 kinase (PI-3K) inhibitors, wortamannin and LY294002 
inhibited CD9 effects on CHO cell motility. In contrast, inhibitors targeting protein 
kinase C (PKC) or mitogen-activated protein kinase (MAPK) had no effect on CD9 
driven CHO cell motility.  
To confirm the key role for PI-3K in CD9 mediated cell migration, 
dominant/negative PI-3K cDNA constructs were used to inhibit endogenous PI-3K 
activity in CHO cells. Motility assays performed on PI-3K dominant/negative transfected 
CD9-CHO cells confirmed that PI-3K was essential for CD9 promoted haptotactic cell 
motility on FN. Consistent with these observations, CD9 expression in CHO cells and in 
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the rat aortic smooth muscle (RASM) cells induced enhanced phosphorylation of Akt, a 
downstream signaling event that reflects PI-3K activity.  
Focal adhesion kinase (FAK) and the adaptor molecule p130Cas are well 
characterized participants in signaling pathways regulating cell motility. FAK acts to 
transmit signaling events from integrins in response to ECM. The activated FAK 
molecule provides a stage for the initiation of multiple signaling events including the PI-
3K/Akt pathway and the p130Cas pathway. The p130Cas adaptor protein participates in 
the p130Cas/Crk pathway, a regulatory mechanism governing directional cell migration 
in many cell types including CHO cells. For these reasons it was important to determine 
the activation states of FAK and p130Cas when CD9 was expressed. As the extent of 
tyrosine phosphorylation of both FAK and p130Cas is directly proportional to their 
activation states, the tyrosine phosphorylation states of these proteins were examined in 
CD9-CHO cells on adhesion to FN.  
In comparison to Mock controls, an increase in p130Cas tyrosine phosphorylation 
was observed in CD9-CHO cells. Under parallel conditions, there were no significant 
changes in FAK tyrosine phosphorylation. Further examination revealed that p130Cas 
total protein levels were considerably increased in CD9 expressing cells compared to 
Mock transfectants. In spite of this observation, no significant changes in the pro 
migratory phenotype of CD9 expressing cells were seen on p130Cas siRNA specific 
knockdown. These data suggest that although p130Cas activation is a consequence of 
CD9 expression, p130Cas dependent pathways are not mandatory for CD9 mediated 
motility on FN. 
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Integrins are cell surface molecules that act as receptors for ECM proteins. CD9 
and other tetraspanins are known to participate in molecular complexes with integrins at 
the cell membrane. Integrin α5β1, the primary cell receptor for FN, plays a key role in 
cellular adhesive responses to FN. For these reasons, it is feasible that CD9 may 
influence the function of α5β1 via physical association at the cell membrane. Co-IP 
studies showed that CD9 was in complex with α5β1 at the cell membrane and CD9/α5β1 
association was detected in cells expressing CD9 both ectopically and constitutively. 
These data demonstrated that CD9/α5β1 complexes were not an artifact formed as a 
result of exogenous CD9 expression.  
In the current study a key role for α5β1 in CD9 mediated cell motility was 
demonstrated by the ability of function blocking monoclonal antibody (mAb) against 
α5β1 to arrest cell motility in CD9-CHO cells. Since integrin α5β1 activation via change 
in conformation is required for cell migration on FN, we examined whether CD9 
expression affected α5β1 conformation state. In order to determine CD9 effects on the 
activation state of α5β1, binding of β1 integrin conformation sensitive antibody (B44) in 
the presence of α5β1 activating peptide (RGDS) was measured in CD9-CHO vs. Mock 
cells. Our results showed that B44 antibody binding was significantly higher in CD9 
expressing cells as compared with the control cells.  
In summary, the study demonstrates key molecular mechanisms governing CD9 
mediated haptotactic cell motility to FN in CHO cells. Our findings indicate that CD9 in 
concert with integrin α5β1 requires activation of the PI-3K pathway leading to enhanced 
haptotactic cell migration on FN.  
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Chapter 1: Introduction 
 
1.1 Tetraspanins as Membrane Proteins 
Membrane proteins represent 25-30% of total proteins encoded by the human 
genome. Integral membrane proteins constitute a subclass of membrane proteins that are 
characterized by the presence of one or more hydrophobic regions in their primary amino 
acid sequence (1). The hydrophobic regions of integral membrane proteins extend 
through the phospholipid bilayer and constitute their transmembrane (TM) domains (2). 
Integral membrane proteins with TM domains are known as transmembrane proteins (3). 
In addition to serving as major structural components of membrane, 
transmembrane proteins mediate important biological functions. Table 1.1 summarizes 
the important biological functions mediated by transmembrane proteins. Based on the 
number of TM domains present in the primary amino acid sequence, transmembrane 
proteins are further classified in to different superfamilies. For example, transmembrane 
proteins with seven membrane spanning domains are known as “seven transmembrane 
proteins”. 
Transmembrane proteins with four membrane spanning regions are classified 
under transmembrane 4 superfamily (TM4SF). TM4SF proteins are also known as 
tetraspanins or tetraspans. Although the presence of four transmembrane domains is a 
requirement for a protein to be a tetraspanin, additional features such as the presence of 
unique motifs in the second extracellular loop is an essential requirement for it to be 
classified as a true tetraspanin.  
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Table 1.1 Biological Functions of Membrane Proteins 
Function Examples 
Membrane Transport Ion channels, Glucose and Amino Acid 
Transporters 
Extracellular Matrix Recognition Integrins 
Cell-cell Interactions Intercellular Adhesion Molecules (ICAMs) 
Soluble Ligand Recognition Growth Factor Receptors 
Signal Transduction Integrins, Growth Factor Receptors, ICAMs 
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Tetraspanins are expressed in all eukaryotic organisms. Homologs of tetraspanins 
have even been reported in the genome of invertebrates such as Drosophila melanogaster 
(4), Caenorhabditis elegans (5), and Schistosoma mansoni (6) suggesting that 
tetraspanins are evolutionarily a highly conserved class of proteins. Genome analysis 
identified that there are about 37 tetraspanin homologs in Drosophila melanogaster (4) 
and about 20 tetraspanins in Caenorhabditis elegans (5).  
A tetraspanin-like protein has been reported from the eukaryotic unicellular 
organism Magnaporthe grisea (7). However, so far, there is no evidence to show that 
tetraspanins are expressed in prokaryotic organisms. Analysis of tetraspanins from 
different organisms shows a high degree of conservation in their primary amino acid 
sequence.  
Mammalian tetraspanins are a widely expressed class of proteins and about 33 
members have been reported (8). With the exception of mature red blood cells (RBC) that 
do not express tetraspanins most mammalian cells express one or more TM4SF proteins 
(9). TM4SF members are often recognized by their alternative names. Table 1.2 shows 
the list of mammalian tetraspanins identified thus far and their alternative names. 
 
1.2 Common Structural Features of Tetraspanins 
Early evidence for the structural organization of the tetraspanins came from 
hydropathic analysis studies of tetraspanin primary amino acid sequence. On average, 
there are about 250 amino acids in TM4SF members with molecular weight ranging from 
22-32 kDa. The predicted structure of tetraspanin is comprised of four transmembrane 
domains (TM1-TM4) and two extracellular domains where the N and C-termini are  
 3
  
Table 1.2 Mammalian Tetraspanins 
           Serial No         Primary Name Alternative Names 
1 Net-1, TM4-C Tetraspanin-1 
2 TSAPN-2 Tetraspanin-2 
3 TSPAN-3 Tetraspanin-3, OAP-1, TM4SF-8 
4 Tspan-4 Tetraspanin-4, NAG-2, TM4SF-7 
5 Net-4 Tetraspanin-5 
6 TM4SF-6 Tetraspanin-6, Tspan-6, T245 
7 TALLA-1 Tetraspanin-7,CD231,TM4SF-2, A15 
8 TM4SF-3 Tetraspanin-8, CO-029 
9 Net-5 Tetraspanin-9 
10 Occulospanin Tetraspanin-10 
11 XP_497334 Tetraspanin-11 
12 NET-2 Tetraspanin-12 
13 Net-6 Tetraspanin-13 
14 DC-TM4F2 Tetraspanin-14 
15 Net-7 Tetraspanin-15 
16 TM4-B Tetraspanin-16,TM4SF-16 
17 SB 134 Tetraspanin-17 
   
 
 4
  
Table 1.2 (Continued) 
Serial No Primary Name Alternative Names 
18 BAB-55318 Tetraspanin-18 
19 XP_08648 Tetraspanin-19 
20 Uroplakin 1b Tetraspanin-20 
21 Uroplakin 1a Tetraspanin-21, UP1 
22 Peripherin Tetraspanin-22, RDS 
23 ROM Tetraspanin-23 
24 CD151 Tetraspanin-24, PETA-3 
25 CD53 Tetraspanin-25 
26 CD37 Tetraspanin-26 
27 CD82 Tetraspanin-27, KAI-1 
28 CD81 Tetraspanin-28, TAPA-1 
29 CD9 Tetraspanin-29, p24, MRP-1, DRAP-27 
30 CD63 Tetraspanin-30, LAMP-3 
31 SAS Tetraspanin-31 
32 TSSC6 Tetraspanin-32, PHEMX 
33 BAB22942.1* - 
 
Note: * Mouse tetraspanin that to date lack a human homolog. 
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located intracellularly. A short intracellular chain links the 3rd and 4th transmembrane 
domains. The first extracellular domain (EC1) is relatively short with about 20-28 amino 
acids when compared to the second extracellular domain (EC2) that contains about 76-
131 amino acids. 
One of the unique features of the tetraspanins is the presence of 4-8 cysteine 
residues in the EC2 domain. Two of the conserved cysteines in EC2 exist in a “CCG” 
amino acid motif that is considered to be the signature sequence of TM4SF (Figure 1.1). 
The cysteine residues of EC2 region including those in the CCG motif participate in 
intrachain disulfide bonds. In addition to this feature, TM4SF proteins often contain polar 
residues such as glutamate and glutamine in their TM3 and TM4 domains (Figure 1.1). 
Thus the overall three dimensional conformation of the EC2 domain is not only 
determined by the number of cysteine residues but also by the permissible disulfide 
linkages among these cysteine residues. Because of the unique conformation of the EC2 
domain, several monoclonal antibodies (mAbs) can bind tetraspanins with high 
specificity. Furthermore, most of the functions mediated by tetraspanins are attributable 
to this region. Figure 1.1 depicts the schematic drawing of a typical tetraspanin protein. 
Mammalian cells express several other membrane proteins that contain four 
transmembrane proteins. For example, proteins such as sarcospan (10), CD20 (11), like 
tetraspanins, contain four transmembrane domains. However, due to the absence of 
unique structural motifs seen in tetraspanins, these proteins are not classified under 
TM4SF. 
Due to the difficulties inherent to purification, stabilization and crystallization of 
membrane proteins, structural information of full-length tetraspanin proteins is not 
 6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic Representation of Tetraspanin Structure 
 
The colored circles represent the highly conserved amino acids of the EC2, 3rd and 4th 
transmembrane domains and the intracellular loop. EC1: Extracellular loop-1, EC2: 
Extracellular loop-2; E: Glutamic acid, C: Cysteine, Q: Glutamine, G: Glycine. 
 
 
 
 
 
 7
available. However, the crystal structure of tetraspanin CD81 EC2 domain has been 
solved (12, 13).  The EC2 domain of CD81 was shown to contain five α–helices arranged 
in a “stalk” and “head” subdomain pattern (12). Comparative structural analysis of other 
tetraspanins indicates that structural features in the CD81 EC2 are common to all 
tetraspanins. The unique domain structure of tetraspanins may facilitate homo/hetero-
dimerization of tetraspanins. 
The N and C terminal cytoplasmic domains of tetraspanins contain very few 
amino acids. The c-terminal cytoplasmic tails of a few tetraspanins have been shown to 
possess a conserved YXXφ (X: any amino acid; φ: hydrophobic amino acid) motif. The 
YXXφ motif of tetraspanins CD151, CD63, and CD82 represents a tyrosine based 
internalization motif that is required for endosomal/lysosomal recycling pathway (14, 
15). 
Transmembrane domains of tetraspanins are deemed essential for proper 
maturation, membrane targeting, and for maintaining intermolecular interactions (16, 17). 
Structurally, transmembrane domains of tetraspanins exhibit some distinctive features. 
For example, transmembrane domains TM1, TM2, possess a heptad repeat sequence with 
glycine as the first amino acid that is thought to be important for intramolecular 
interactions. TM3 domain, in addition to containing the heptad repeat, also contains 
highly conserved polar amino acid residues glutamate, glutamine in its sequence. TM4 
domain lacks the heptad repeat sequence but contains the conserved polar amino acids 
glutamate and glutamine (16) (Figure 1.1). 
Perhaps the most significant consequence of the tetraspanin structure is their 
ability to organize membrane proteins into distinct microdomains within membranes. 
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Depending on the structural configuration of the EC2 domains, tetraspanins can associate 
with a wide variety of membrane proteins. Tetraspanin containing membrane protein 
complexes have been termed as tetraspanin enriched microdomains or TEMs (18). Within 
the TEMs, a few tetraspanins such as CD151 and CD81 are known to have a highly 
stoichiometric and avid physical interaction with other membrane proteins (3, 19). These 
interactions mediated by CD151 and CD81 are retained even after harsh detergent (1% 
Triton-X100) treatment and reported to be due to direct interactions as demonstrated by 
chemical cross linking experiments (20). Other tetraspanin members reported to have 
direct interactions include the Uroplakins (21).  
The direct interactions of CD151 and CD81 with other membrane proteins are 
thought to be mediated by their EC2 domains and are characterized by resistance to 
highly hydrophobic detergents such as Triton-X100. The dimerization motifs in the EC2 
regions of few tetraspanins such as CD81 may also aid in the formation of homo/hetero 
dimeric complexes within the TEM. Most tetraspanins cannot maintain direct interactions 
described above and are thought to enter primary tetraspanin complexes by secondary 
associations. These secondary associations are easily disrupted by stringent detergents 
such as Triton-X100 but resist separation by mild detergents such as CHAPS and Brij-98 
(22). Secondary tetraspanin interactions are non stoichiometric and factors such as 
palmitoylation of tetraspanins were shown to significantly influence the nature of these 
interactions (23). 
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1.3 Biological Significance of Tetraspanins 
Although tetraspanins are widely studied, little knowledge has been attained in 
understanding the true biological significance of these proteins.  Tetraspanins are known 
to form non-covalent associations with a wide variety of cell surface proteins. The 
complexity of tetraspanin interactions with other membrane proteins together with their 
broad tissue distribution makes tetraspanins a difficult family of proteins to understand in 
terms of their biological function. Tetraspanins, in addition to contributing to the 
structural framework of membranes, are also involved in several important biological 
processes such as embryonic development, infection by pathogens, and tumor cell 
metastasis. 
The integrin family of adhesion molecules was the first group of membrane 
proteins detected in complex with tetraspanins. Structurally, integrins are heterodimeric 
molecules comprised of α and β subunits (24-26). So far, about 18 α and 8 β subunits of 
integrins have been characterized. Via the combination of α and β subunits, 24 integrins 
are expressed in the mammalian cells. Tetraspanins have been detected in complex with 
integrins containing β1, β3, and β4 subunits. Tetraspanin associations, with β1 integrins 
in particular, are thought to modulate integrin mediated cell adhesive phenotypes (19, 27, 
28). Often more than one type of tetraspanin is present in the integrin-tetraspanin 
complexes and integrin-tetraspanin complexes in the cell membrane are thought to form a 
network known as the “tetraspanin web” (9).  
Other cell surface molecules that can exist in complex with tetraspanins include 
the Ig superfamily of proteins, growth factors, and immune cell markers such as cluster 
differentiation (CD) and major histocompatibility (MHC) proteins. More specifically, 
 10
CD81 and CD9 associate with Ig superfamily of protein EWI-2 (29). Evidence also 
suggests that tetraspanins may actually link members of the Ig superfamily with integrins 
thus modulating their functions (30). Additionally, CD81 was reported to associate with 
the helper T-lymphocytes marker CD4 (31) and CD9 was shown to associate with IgM 
(32).  
So far few growth factors and their receptors have been detected in complex with 
tetraspanins. CD9 was shown to associate with and modulate the activity of membrane 
bound form of heparin binding epidermal growth factor-like growth factor (Pro-HBEGF) 
and modulate Pro-HBEGF activity (33, 34). Recently, CD9 and CD81 were isolated from 
ganglioside enriched microdomains along with the fibroblast growth factor receptor (35). 
Functional implications of tetraspanin-growth factor receptor interactions are still under 
investigation. 
Tetraspanins have been shown to participate in integrin-associated cell signaling 
pathways. A specific link between α3β1, the tetraspanin CD151, and PI 4-kinase was 
observed where the PI 4-kinase activity was shown to be associated with CD151 
immunoprecipitates (36, 37). This report was the first demonstration of a direct 
association between a tetraspanin member and an intracellular signaling molecule that 
regulates the cytoskeleton. Subsequently, other tetraspanins such as CD9, CD63, CD81 
and TALLA-1 have also been reported to associate with PI 4-kinase (20). 
Tetraspanins have also been shown to influence the association of α3 integrin 
containing complexes with specific isoforms of PKC. The formation of integrin-
tetraspanin-PKC complexes was thought to influence localization of additional signaling 
complexes that regulate cytoskeletal organization (38). A recent study of TM4SF 
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member, CD82, in the prostate cancer cell line DU145, suggested that modulation of 
p130Cas protein levels and its activation represents a mechanism by which TM4SF 
members influence cell motility and cancer metastasis (39).  
Several studies have shown evidence for the role of tetraspanins in the regulatory 
processes of pathogen mediated infections. Tetraspanin CD81 was reported to act as a 
receptor for hepatitis C virus (Hep-C) (40). More specifically, the regions of CD81 that 
are involved in Hep-C binding were mapped to the EC2 domain (amino acids: 164-201) 
where anti- CD81-EC2 mAbs also blocked Hep-C- CD81 binding. Although CD81 was 
the first receptor identified for Hep-C, several recent studies have shown that CD81 alone 
is not sufficient for Hep-C infection (41, 42). Recently, CD81 was also shown to play a 
role in the pathogenesis of malaria (43). Using hepatocytes from CD81 knockout mice 
and blocking antibodies against CD81, Silvie et al, 2003 (43) have shown that CD81 is 
required for the entry of Plasmodium sporozoites into hepatocytes, an essential step for 
completion of Plasmodium life cycle. 
Other tetraspanins that have been shown to take part in the etiology of infections 
include the tetraspanins CD82, CD63 and CD9. Antibodies to CD82 inhibited human T-
lymphotropic virus-1 (HTLV-1) induced syncitia of cultured cells (44, 45). Similarly, 
antibodies to CD63 inhibited human immuno deficiency virus type-1 (HIV-1) infection in 
cultured cells (46). Antibodies to CD9 and CD81 modulated HIV-1 induced syncitia 
formation of cultured cells (47).  
In addition to participating in pathogenesis, tetraspanins also modulate the host’s 
immune response to infections. Several tetraspanins associate with proteins that are 
directly or indirectly involved in modulating immune response. For example, tetraspanins 
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CD9, CD81, CD63 and CD53 were all shown to associate with the class II major 
histocompatibility complex proteins that are important in antigen presentation to the 
immune cells (48). In T helper lymphocytes, CD81 and CD82 associate with CD4 (31), 
the primary receptor for HIV-1 viral entry. Additionally, tetraspanins have been 
implicated in the regulation leukocyte activation, migration, and response to antigens 
(49).  
The role of tetraspanins in the regulation of tumor cell metastasis has been 
intensely investigated. Expression of various tetraspanins appears to significantly vary 
during the natural course of tumor growth and early reports have even proposed several 
tetraspanins as useful markers of tumor cells. For example TALLA-1 has been reported 
as a marker for T-lymphoid leukemias (50) while CD9 was recognized as a marker for B 
cell acute lymphoblastic leukemias (51). More recent studies have questioned the 
usefulness of tetraspanins such as CD9 as useful tumor markers, as some tumor cell types 
do not have the predicted tetraspanin expression profile (52). Although tetraspanins such 
as CD82 appear to be in general suppressors of tumor cells metastasis, a consensus has 
not been reached with regard to the role of many other tetraspanins in tumorogenesis and 
metastasis (53). 
 
1.4 Genetic Evidence for the Biological Significance of Tetraspanins 
Functionally relevant tetraspanins have been reported in invertebrates such as 
Magnaporthe grisea, Drosophila melanogaster, and Schistosoma hematobium. In 
Magnaporthe grisea, a pathogenic fungus that infects rice leaf, PLS1 gene has been 
shown to encode a tetraspanin-like protein. Inactivation of PLS1 was shown to impair the 
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ability of the fungus to penetrate rice leaf cells suggesting that PLS1 gene product is 
essential for parasite entry in to the host cells (7). Genetic analysis also showed that the 
late bloomer (lbl) gene in Drosophila melanogaster encodes tetraspanin protein, where 
specific mutations of lbl were shown to delay synapse formation at neuro-muscular 
junctions (54).  
One of the early genetic evidences for the biological significance of mammalian 
tetraspanins came from the observation that a balanced translocation involving X-
chromosome inactivated T-cell acute lymphoblastic leukemia associated antigen-1 
(TALLA-1) causing a form of X-linked mental retardation (55). Although originally 
identified as a leukemic T-cell antigen, TALLA-1, a tetraspanin is abundantly expressed 
in the central nervous system of human (55) and mice (56) suggesting that TALLA-1 
may be important for functional maturation of nervous tissue.  
Gene knockout studies have become a common method of studying the functional 
role of proteins. By engineering the mouse embryonic stem (ES) cells, it is possible to 
generate a transgenic mouse lacking the protein [knockout (KO)] of interest in all tissues. 
The consequence of gene knockouts for five different tetraspanins, CD9, CD81, CD37, 
CD151, and Tssc 6 have been investigated. Table 1.3 summarizes the major phenotypic 
changes reported in the tetraspanin KO mice. 
The first tetraspanin KO phenotype reported was for CD9. Three independent 
groups have reported that female mice deficient in CD9 have reduced rates of fertility due 
to failure of oocytes to fertilize with sperm (57-59). Aside from reduced fertility, CD9 -/- 
mice were healthy without any noticeable abnormalities. Tetraspanin TSSC also known 
as tetraspanin-32 or PHEMX is highly expressed in the hematopoietic and lymphoid  
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Table 1.3 Major Phenotypic Differences in Tetraspanin Knockout (KO) Mice 
 
Tetraspanin KO Phenotype 
CD9 Reduced Fertility in Female Mice 
CD151 
 
Renal Failure 
Hemostasis Abnormality 
Impaired Outside-in Signaling in Platelets 
CD81 Reduced Fertility in Female Mice 
Reduced Infectivity of Hepatocytes with Malarial Parasite 
Reduced Expression of CD19 and Ca2+ Signaling in B Cells 
CD37 Reduced T dependent B cell Immune Response 
TSSC6 Impaired Outside-in Signaling in Platelets 
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system (60). Despite high level of expression in these tissues, no significant abnormalities 
were observed in the development of hematopoietic and lymphoid system of TSSC -/- 
mice (61). The only major phenotypic differences observed in TSSC6 -/- mice was 
defective GPIIb/IIIa mediated “outside-in” signaling in platelets (62) and abnormal in 
vitro proliferative response of T- cells to antigens (61).  
Tetraspanin CD37, also known as tetraspanin-26, was originally reported as a 
marker for B lymphocyte tumor cells (63) and was subsequently detected on several cells 
of the immune system (64). However, CD37 -/- mice did not exhibit significant 
anomalies in lymphoid organ development (64). The only abnormality observed in the 
CD37-/- mice appears to be the anomalous humoral immune response of B cells to T-
cell-dependent antigens (64).  
CD81, also known as TAPA-1 has a wide tissue distribution. The phenotype of 
CD81-/- mice was originally reported by Shoham et al, 2003 where CD81 deletion 
downregulated CD19 expression on B cells (65). CD81 was shown to associate with 
CD19, a unique marker of B cells (66). Subsequently, Silvie et al, 2003 reported that 
Plamodium yoelii sporozoites failed to infect CD81 -/- hepatocytes and CD81 expression 
in hepatocytes is required for differentiation of parasite into exoerythrocytic forms (43). 
Recently, CD81 -/- female mice were shown to have reduced fertility, the phenotype 
characteristic of CD9 -/- female mice (67). 
CD151 is widely expressed tetraspanin and the CD151 KO phenotypes have been 
characterized. The predominant abnormalities of CD151 KO are associated with platelet 
function. CD151 -/- mice had minor bleeding abnormalities with prolonged bleeding 
times and increased incidence of rebleeding (68). In accordance with the bleeding 
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anomalies observed in the CD151 -/- mice, platelets derived from CD151 -/- mice were 
shown to have impaired agonist induced GPIIb/IIIa mediated “outside-in” signaling 
response and diminished spreading on fibrinogen (FG) (69). CD151 -/- mice were also 
prone to renal failure (70).  
Results from the KO models clearly indicate that the tetraspanins are dispensable 
for normal intra uterine growth and development of mice. Although tetraspanins CD81, 
CD9, CD37 are expressed in different sub populations of B lymphocytes, complete 
formation of mature B lymphocytes does not appear to require a full complement of 
tetraspanins. Despite abundant expression of tetraspanins CD9 and CD151 on platelets, 
hemostasis abnormalities thus far appear to be limited to CD151 -/- mice. Lack of CD9 
did not influence formation or renewal of platelets or marginal Zone B cells where it is 
abundantly expressed.  
A feature common to CD9 and CD81 homozygous deletion is the failure of KO 
murine ova to fuse normally with sperm. Interestingly, CD9, CD81 double KO mice were 
shown to be completely infertile as opposed to the partial infertile phenotype observed 
with CD9, CD81 single gene deletion (67). These findings suggest that tetraspanins have 
overlapping functional roles and that absence of one tetraspanin may lead to possible 
functional compensation by another closely related member. 
 
1.5 History and Molecular Biochemistry of Tetraspanin CD9 
Human CD9 was first reported via its reactivity with the monoclonal antibody 
(mAb), BA-2, raised against leukemic cell line, NALM-6 (51). The BA-2 antibody 
immunoprecipititaed a protein with a molecular weight of 24 kDa and was termed the 
 17
p24 antigen. Immunofluorescence assays demonstrated that p24 is a cell surface protein 
present on several bone marrow precursor cells of the lymphopoietic lineage. 
Subsequently, several mAbs were generated that specifically recognized p24 antigen 
expressed on a variety of cells (71-74). p24 antigen was named as the cluster of 
differentiation 9 (CD9) at the First International Workshop on Leukocyte Differentiation 
Antigens in the year 1984 (75).  
Using specific DNA probes, the gene encoding p24/CD9 was localized to the 
short arm of chromosome 12 (76). The primary structure of p24/CD9 was elucidated in 
1991 where CD9 cDNA was isolated from a megakaryocytic library. The CD9 gene 
consists of 8 coding regions (exons) that span about 20 Kb region of genome. 
Transcription of the CD9 gene generates a 1.4 Kb mRNA that encodes a protein of 228 
amino acids with an apparent molecular weight of to a 24 kDa (77).  
Prototypically, CD9 is comprised of four highly hydrophobic transmembrane 
(TM) regions designated TM1-4, two extracellular regions (EC1 and EC2) and NH2 and 
COOH terminal cytoplasmic tails. Topography studies of CD9 reveal that both the N-
terminal and C-terminal regions are located in the cytosolic portions of the cell (77). The 
TM domains of CD9 are also highly conserved including Glu or Gln residues within the 
3rd and 4th TM domains (Figure 1.1). There are a total of ten cysteine residues in the 
primary amino acid sequence of CD9 and the conserved CCG motif is localized to the 
EC2. Figure 1.2 shows the primary amino acid sequence of CD9 with mapping of 
various structural domains.  
Most integral membrane proteins are post translationally modified by the addition 
of one or more oligosaccharide chains (78). Addition of oligosaccharide chains 
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(glycosylation) can occur either on the OH group of amino acids serine and threonine (O-
linked glycosylation) or on the NH2 group of arginine (N-linked glycosylation). N-linked 
Glycosylation of tetraspanins has been hypothesized to regulate their functions (79). 
Primary amino acid sequence of CD9 reveals the presence of a classical N-linked 
glycosylation motif (NXaaS/T) in the EC1 region. Although CD9 lacks the NXaaS/T 
motif in the EC2 region, NXaaC sequence of the EC2 was thought to be glycosylated, 
however, the functional consequences of CD9 glycosylation are as yet unknown (80). 
Membrane proteins are also known to undergo post translational modification by 
the addition lipids (81). Such lipid modifications are thought to be important for targeting 
proteins to the membrane and for their assembly into multimeric complexes. 
Palmitoylation is a reversible lipid modification where fatty acids such as palmitic acid 
are added to cysteine residues of membrane proteins. Studies indicate that CD9 
undergoes palmitoylation (23) and that palmitoylation may be critical for maintenance of 
tetraspanin-integrin interactions (82).  
 
1.6 Expression and Tissue Distribution of CD9 
Although originally identified in the cells derived from the hematopoietic lineage, 
CD9 is also constitutively expressed in several other tissues. Within the hematopoietic 
system, CD9 expression is most abundant in the megakaryocyte lineage where both 
platelets and megakaryocytes express large quantities of CD9 (72, 83-85). CD9 
expression has been detected on other hematopoietic derived cells including macrophages 
(86), eosinophils (87), basophils (88) and the lymphoid lineage (89). Although CD9 
expression is not seen in the mature circulating/peripheral B and T lymphocytes (51), 
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bone marrow lymphopoietic cells and mitogen activated lymphocytes however, express 
significant levels of CD9. In the nascent B cell sub population of spleen, CD9 is uniquely 
expressed on the marginal zone B (MZB) cells (89). 
In the vascular system, CD9 is expressed on endothelial cells (90, 91) of the 
tunica intima and on vascular smooth muscle cells (92, 93) of the tunica media. The 
abnormal migration and proliferation vascular smooth muscle cells and endothelial cells 
are cellular events that occur during atherosclerosis and other major vascular disorders. 
Interestingly, CD9 has been implicated in the regulation of cell migration in both vascular 
smooth muscle cells and endothelial cells (91, 92). 
CD9 expression is also found on ectodermal derived nervous tissue, where a mAb 
specific for human CD9, B2C11, induced morphological changes and promoted neurite 
outgrowth in the cultured neurons (94). CD9 is highly expressed in the developing mouse 
brain as well as in the adult mouse neuronal components such as the glial cells and the 
myelin sheaths (95). In the peripheral nervous system, CD9 is expressed on Schwann 
cells where anti-CD9 mAbs modulate in vitro Schwann cell migration (96). 
In the reproductive system CD9 is expressed on the surface of oocytes. Oocytes 
derived from human (97), pig (98) and mouse (58) expressed CD9 where CD9 expression 
is essential for sperm-egg fusion. CD9 is also found on extra villuous trophoblasts (99) of 
the gravid uterus and the granulose cells of the ovary (100). CD9 is also expressed on all 
the living layers of epidermis (101) and on cultured fibroblasts and osteoclasts. Several 
tumor cells including those derived from hematopoietic lineage of cells also express 
CD9. Importantly, the extent of CD9 expression is altered on tumors and it has been 
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proposed that there is a relationship between CD9 expression and metastatic potential in a 
number of human cancers. 
 
1.7 Functional Significance of CD9 in Platelets 
CD9 is abundantly expressed on the surface of platelets. One of the earliest and 
most striking observations related to platelet CD9 function is the ability of anti-CD9 
mAbs to cause platelet activation and aggregation (102, 103). Most of the anti-CD9 
mAbs tested induce platelet aggregation evev in the absence of exogenous fibrinogen. 
Furthermore, platelet aggregation induced by anti-CD9 mAbs requires the intact 
immunoglobulin antibody. Purified Fab fragments derived from anti-CD9 mAbs were 
unable to elicit platelet aggregation. Based on these findings, it has been hypothesized 
that anti-CD9 mAbs induce platelet aggregation response by cross linking the Fc 
receptors and CD9.  
Platelets also express tetraspanins CD151 (69) and CD63 (104). In resting 
platelets, both CD9 and CD151 are located at the platelet membrane where activation of 
platelets does not change the surface expression of these tetraspanins. Conversely, in 
resting platelets CD63 is predominantly localized to the intracellular granules (105) and 
platelet activation and degranulation promotes CD63 translocation to the peripheral 
membrane resulting increased CD63 levels at the platelet surface (106).  
Another interesting feature of platelet CD9 is its ability to form complexes with 
the platelet integrin GPIIb/IIIa (αIIbβ3). GPIIb/IIIa, the fibrinogen receptor abundantly 
expressed on platelets, is essential for platelet aggregation where mutations in GPIIb/IIIa 
lead to an inherited bleeding disorder known as Glanzmann’s thrombasthenia (107). The 
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earliest reports of CD9/ GPIIb/IIIa association came from the studies of Slupsky et al, 
1989 (108). Subsequently several groups have confirmed this observation (84, 109, 110). 
Scanning electron microscopy studies have revealed that in activated platelets, CD9 and 
GPIIb/IIIa specifically localizes to membrane protrusions and platelet-platelet contact 
sites (84) suggesting that CD9 may participate in the regulation of adhesion dependent 
phenomena in platelets.  
In addition GPIIb/IIIa, CD9 has been detected in complex with other major 
platelet membrane proteins such as the von Willebrand factor (vWF) receptor GPIb/V/IX 
(110). The functional consequences of CD9 with either GPIIb/IIIa or the GPIb/V/IX 
complexes are largely unknown, and it is speculated that CD9 may regulate the activation 
states of these glycoproteins. In addition to mediating protein-protein interactions in the 
platelets, CD9 was also shown to modulate intracellular signal transduction pathways 
within the platelets. Treatment of platelets with anti-CD9 mAbs alter intracellular 
calcium influx (111), phosphoinositide turnover, signaling through PKC, and platelet 
cytoskeletal reorganization (102). 
Since CD9 is also expressed on the platelet precursor, the megakaryocytes, it is 
also speculated that CD9 may be required for megakaryocyte lineage development and 
platelet formation. Despite the effects of anti-CD9 mAbs on platelets, platelet function 
abnormalities have not have been reported in CD9 knockout mice. At least in the mouse 
model, even in the absence of CD9, platelets appear to be formed with normal structure 
and function. Although the reasons for the above observed discrepancies are unclear to 
date, it can be speculated that in the absence of CD9, other tetraspanins expressed on the 
platelets may have compensatory effects.  
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1.8 The Role of CD9 in Modulation of Adhesion Dependent Phenomenon 
Since the identification of CD9 as a cell surface protein, numerous studies have 
been performed to understand the biological significance of CD9 in a cellular context. 
The role of CD9 in the modulation of adhesive phenotypes have been investigated by the 
following approaches; 1) examination of CD9 expression profiles in cells at various 
stages of cancer progression to determine a correlation between CD9 expression levels 
and changes in cancer cell motility or tumor metastasis; 2) the ability and effects of anti-
CD9 mAbs in the modulation of cells phenotypes; and 3) modulation of CD9 expression 
and its effects on adhesive cell phenotypes. Due to extensive evidence linking CD9 
expression to cell motility, CD9 is also known as Motility Related Protein (MRP-1). The 
studies that point to CD9 as an important regulator of cell motility are summarized 
below.  
Altered expression of cell surface adhesion molecules in tumor cells is one of the 
major factors determining the metastatic potential. CD9 expression was shown to 
correlate well with the metastatic potential of various tumor cells. Miyake et al, 1996 first 
reported decreased expression of CD9 in the advanced breast cancer tissue when 
compared to CD9 expression in primary breast cancer tissue (112). Subsequently, a 
negative correlation between CD9 expression and metastatic potential of tumors has been 
reported in lung adenocarcinoma (113), esophageal (114) and oral squamous cell 
carcinomas (115), and small cell cancer of the lung (116).  
In contrary to the above reports, expression of CD9 has also been shown to 
positively correlate with the metastatic potential of certain tumor cells. For example, in 
colon cancer cells CD9 expression was shown to be high at the primary site as opposed to 
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the regions of metastasis (117). Sauer et al, 2003 reported a strong expression of CD9 on 
the cervical cancer cells near the sites of transendothelial invasion of these cells (118). A 
positive correlation between CD9 expression and late stage of cancer has also been 
reported in gastric carcinoma (119).  
The role of anti-CD9 mAbs in the perturbation of cell motility has been 
investigated by several researchers. Masellis-Smith et al, 1990 first reported that several 
CD9 specific mAbs induced homotypic aggregation of the B-lymphoblastoid cell line, 
NALM-6 (120). Subsequently, the ability of CD9 mAbs to modulate cell motility has 
been studied in several model systems yielding contradictory results, where anti-CD9 
mAbs have been shown to have both stimulatory and inhibitory effects on cell migration.  
Anti-CD9 mAbs inhibited migration of lung adenocarcinoma cells (121), 
Schwann cells (96), neuronal cell bodies (95), endothelial cells (91) colon cancer cells 
(117), transendothelial migration of melanoma cells (122), and parietal endodermal cell 
migration (123). Conversely, anti-CD9 mAbs promoted endometrial cancer cell 
migration (124), motility of melanocytes (125) and keratinocytes (126). Several 
researchers have also studied the role of CD9 in cell motility by altering the surface 
expression of CD9.  
Most of the studies examined the phenotypic effects of ectopic expression of CD9 
in cells lacking constitutively expressed CD9. Ikeyama et al, 1993 first reported that CD9 
expression in the lung adenocarcinoma cell line MAC-10, suppressed cell motility (127). 
Subsequently, ectopic expression of CD9 was shown to inhibit motility (116) and 
metastatic potential (128) of small cell lung cancer. Ectopic expression of CD9 promoted 
cell migration in the CHO cells (129) and Raji cells (28).  
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Additional evidence for the regulatory role of CD9 on cell motility came from the 
downregulation of endogenous CD9 expression by siRNA mediated gene silencing. 
Penas et al, 2005 reported that siRNA silencing of CD9 in melanoma cells inhibited cell 
motility (130). Recombinant EC2 regions and peptides corresponding to the EC2 region 
were also able to modulate cell motility. For example, a peptide corresponding to the 
CD9 EC2 amino acids 168-192 was shown to inhibit CD9 promoted haptotactic cell 
motility on FN (129) and a recombinant CD9-EC2 protein inhibited transendothelial 
migration of leukocytes (90). 
The variations observed for the regulatory role of CD9 in different experimental 
approaches can be attributed to broad definition of the cell motility. Haptotaxis, 
chemotaxis and cell invasion are commonly referred as cell motility although 
independently these phenomena are governed by functionally distinct environmental 
cues. Furthermore, differences in the type/s of the extracellular matrix proteins used in 
the cell motility experiments introduce another variable in critically understanding the 
regulatory role of CD9 in cell motility.  
In addition to participating in cell motility, CD9 was also shown to regulate cell 
fusion. Biological phenomenon dependent on CD9 mediated cell fusion include sperm-
egg fusion, viral infectivity of cells, and formation multinucleated cells. One of the 
striking phenotypes of CD9 knockout mice (CD9 -/-) is the decreased ability of the ova 
derived from CD9 -/- mice to fuse with sperms resulting in reduced fertility (57-59). CD9 
has been shown to associate with the integrin α6β1, a known receptor for the sperm 
protein fertilin (131). Subsequently, Kaji et al, 2002 have shown that that infertility of 
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CD9 -/- oocytes can be reversed by exogenous expression of functional human CD9 
mRNA or mouse CD81 mRNA sequences (132).  
Additional evidence for CD9 in sperm-egg fusion came from the studies where 
anti-CD9 mAbs and recombinant proteins corresponding to CD9 EC2 regions were 
shown to inhibit sperm-egg binding and fusion process (133, 134). These studies have 
shown that CD9 EC2 region is essential for sperm-egg fusion. Interestingly, CD81 has 
recently been shown to participate in the sperm-egg fusion process. Rubinstein et al, 2006 
reported that deletion of the CD81 gene in mice resulted in female infertility due to a 
defect in oocyte/ sperm fusion (67).  
In vitro experimental results also suggest that CD9 is involved in muscle cell 
fusion and myotube formation (135), in osteoclastogenesis (136) and in the modulation of 
HIV-1 induced membrane fusion process (47). Tachibana et al, 1999 reported that anti-
CD9 mAbs perturb differentiation of myoblasts into myotubes (135). Overexpression of 
CD9 in a cultured myoblast cell line enhanced syncitia formation characteristic of the 
myotubes while antibody blockade delayed syncitia formation. 
The cell fusion process is also important in the generation of osteoclasts. 
Osteoclasts are macrophage derived multinucleated cells that aid in bone remodeling. 
CD9 is highly expressed on the surface of osteoclasts and in vitro experimental results 
suggest that anti-CD9 mAbs can inhibit the formation of osteoclasts (136). An important 
regulatory role for CD9 in viral infections has recently been explored. Gordon-Alonso et 
al, 2006 reported that treatment of cells with mAbs for CD81 and CD9 or inhibition of 
CD81 or CD9 expression enhanced HIV-1 induced syncytia formation where as 
overexpression of CD81 or CD9 inhibited virus induced syncitia formation (47). 
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From the above observations it is clear that the mechanisms utilized by CD9 in 
the modulation of adhesive cellular events involves complex processes that are 
influenced by the expression of other adhesion receptors, the definition of ECM and other 
experimental variables including proteinases and growth factors. Additionally, the results 
suggest that there is functional redundancy among tetraspanins. For example, most of the 
CD9 regulated cell fusion processes are also regulated by CD81. Among 32 other 
mammalian tetraspanins identified so far, CD9 has the closest amino acid sequence 
homology to CD81 (13) suggesting that structurally related tetraspanins may have  
significantly overlapping functions.  
 
1.9 CD9 Interactions with Cell Surface Molecules 
Tetraspanins are characterized by their unique ability to participate in extensive 
lateral interactions with other membrane proteins. CD9 was the first tetraspanin shown to 
associate with the other membrane proteins. Association of CD9 with platelet GPIIb/IIIa 
(αIIbβ3) was first reported by Slupsky et al, 1989 (108). Subsequently most of the other 
tetraspanins have also been shown to associate with integrins (137). Figure 1.3 shows the 
CD9 binding partners identified in various cells. 
After initial identification of CD9 interaction with integrin β3 (108), several 
groups have reported association of CD9 with β1 containing integrins (138). CD9 
interactions with integrins are highly cell type specific. For example, a part from 
platelets, CD9 has not been shown to associate with β3 integrins. CD9-β1 association 
also appears to be highly specific. In various cell systems, CD9 was shown to be in 
complex with α3β1, α4β1, α5β1, α6β1, and α6β4 integrins. A summary of the 
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Figure 1.3 Molecular Interactions of CD9 with Membrane Proteins 
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functional relevance of CD9 interactions with various β1 integrins is presented below. 
Integrin α3β1 is the receptor for the ECM protein laminin (LN) (139). An 
association between CD9 and α3β1 was first reported on epidermal cells (140). CD9-
α3β1 complexes are often seen with other membrane proteins such as gangliosides (141) 
and pro-HB-EGF (142). CD9 in the α3β1-ganglioside complex was shown to modulate 
cell motility on LN (143).  
Integrin α4β1 is the primary receptor for vascular cell adhesion molecule-1 
(VCAM-1) (144, 145) and α4β1 can bind FN (146). α4β1 is expressed predominately on 
immune cells such as lymphocytes, eosinophils, and monocytes (144). As association 
between CD9 and α4β1 has been reported in the leukemic pre-B cell line, NALM-6, and 
the megakaryocytic cell line, HEL (138). Although both anti-CD9 and anti-α4β1 mAbs 
induce cell aggregation and inhibit cell migration in NALM-6 cells (138), whether CD9 
directly modulates α4β1 interactions with its ligand, VCAM-1, is unknown. 
Integrin α5β1 is the primary receptor for FN (147).  
Like most other CD9-integrin interactions, CD9-α5β1 complexes appear to be 
restricted to few cell types. In NALM-6 cells, CD9 was shown to associate with integrin 
α5β1 (138). Other cell lines where CD9 complexes with α5β1 include the trophoblasts 
(99) and the myocytes (135). However, the physiological significance of CD9-α5β1 
interactions is not known. 
CD9-α6β1 interactions have been reported in a variety of cells such as parietal 
endodermal cells (123), granulosa cells (100), oocytes (133), and Schwann cells (148). 
α6β1 in oocytes interacts with fertilin-beta (ADAM 2) on sperm cell surface (133). 
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Although the functional implications of CD9/α6β1 interactions is not clear, anti-CD9 
mAbs have been shown to modulate Schwann cell (148), parietal endodermal cell 
migration (123), and block sperm-egg fusion (133, 134). A functional association 
between CD9 and LN binding integrin α6β4 has been reported. In cultured keratinocytes, 
CD9 was shown to be in complex with α6β4 (126) and anti-CD9 antibodies have been 
shown to modulate α6β4 dependent cell motility (101, 126) and spreading (82).  
Other members of tetraspanin family are an invariable component of CD9-
integrin complexes. The majority of CD9 complexes isolated from cells by 
immunoprecipitation (IP) contain one or more other tetraspanin member as well as 
integrins. The network of integrins and tetraspanins in biological membranes are termed a 
“tetraspanin web” (149). It has been hypothesized that the composition of the 
“tetraspanin web” can have a significant effect on how integrins function, which in turn 
determines cellular phenotype. 
The most common tetraspanins seen in CD9 immune complexes include CD151, 
CD81, and CD82 (82, 150).  CD151 and CD81 are the only tetraspanins that retain 
association with integrins even under stringent detergent conditions such as Triton-X100 
(22). Since CD9 interactions with integrins are disrupted by stringent detergents, it is 
thought that CD151 and CD81 are required to maintain CD9/integrin interactions.  
Apart from adhesion molecules, so far, only a few growth factor family members 
have been shown to associate with CD9. The membrane-anchored heparin binding 
epidermal growth factor-like growth factor precursor (pro HB-EGF) is a transmembrane 
protein that belongs to the EGF superfamily (151). Pro-HB-EGF is a known diphtheria 
toxin receptor (DTR) (152). An association between CD9 and Pro-HBEGF has been 
 31
reported, where CD9 EC2 was shown to be essential for its interaction with Pro-HB-EGF 
(34, 153). Expression of CD9 was also shown to upregulate the juxtacrine growth factor 
activity of Pro-HB-EGF (33).  
Another growth factor family member that was shown to be in complex with CD9 
is transforming growth factor-α (TGF-α). TGF-α is a member of epidermal growth factor 
(EGF) family (154) and structurally related to HB-EGF (155). TGF-α, synthesized as a 
transmembrane protein, undergoes ectodomain cleavage to release the soluble form of 
TGF-α that activates EGF receptor (156). CD9 association with TGF-α was shown to 
decrease TGF-α susceptibility to ectodomain cleavage (157).  
Major histocompatibility complex class II (MHC class-II) proteins are expressed 
on a wide variety of antigen presenting cells in the immune system (158). Dendritic cells 
(DC) are the antigen presenting cells that express both MHC class-II and CD9 (48, 159). 
In DC, CD9 has been detected in complex with MHC class-II molecules at the cell 
membrane (48). Engering et al, 2001 proposed that association of tetraspanins with the 
MHC class-II molecules is required for redistribution of MHC class II to the various 
compartments of DC. In support of this observation, the intracellular tetraspanin, CD63, 
was predominantly associated with intracellular MHC class-II (48) and cell surface CD9 
was required for heterologous association of MHC class-II molecules with other 
membrane proteins (160). 
CD9 has also been found in complex with Ig superfamily of proteins. EWI-2 is a 
recently identified member of the Ig superfamily of proteins that associates with 
tetraspanins CD9 and CD81 at high stoichiometry (29). Another Ig superfamily member 
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found in complex with CD9 is IgM (32). Interactions between either CD9 or CD81 with 
EWI-2 were essential for recruiting of integrins in to tetraspanin/EWI-2 complexes (30).  
Fc receptors (FcR) are the cell surface molecules that recognize Fc portions of the 
immunoglobulins and mediate immunological phenomenon such as antibody mediated 
phagocytosis and complement activation. CD9 association with FcR has been reported in 
macrophages (161) and in platelets (162). Where CD9 was shown to be associated with 
FcR, anti-CD9 mAbs induce cross linking of FcR, leading to the activation of cells (161, 
162). 
 
1.10 CD9 and Ligand Interactions 
In addition to extensively participating in lateral interactions with other membrane 
proteins, CD9 was also shown to serve as a receptor for both soluble and insoluble 
extracellular components.  At least three extracellular proteins have been shown to act as 
ligands for CD9. Table 1.4 summarizes the list of CD9 ligand interactions that were 
reported to date. The first reported protein shown to bind CD9 was FN (129). FN is an 
extracellular matrix protein that is involved in several important biological processes 
such as embryogenesis, tissue remodeling/repair, and blood coagulation. Integrin α5β1 is 
the classical FN receptor and interaction of α5β1 with FN regulates the important cellular 
functions such as cell adhesion, migration and extracellular matrix assembly (147, 163, 
164). 
FN is a 450 kDa dimeric protein comprised of two identical 225 kDa polypeptide 
chains joined by disulfide bonds (165). Structurally FN is composed of three types of  
repeating modules referred to as type1, type II, and type III repeats (166). Groups of  
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Table 1.4 Ligand Interactions of CD9 
 
Ligand Cell Type / Source of CD9 Functions 
PSG17 Monocyte and Macrophages Immune Response 
IL-16 Mast Cells Chemotactic Response 
Fibronectin Platelet Purified and 
Recombinant CD9 
Cell Spreading, Motility, 
Pericellular FN Matrix 
Assembly 
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modules are folded into six globular domains that bind various extracellular and cell 
adhesion molecules (167). Integrin α5β1 is the primary cell surface receptor for FN and 
recognition of FN by α5β1 requires the RGD (Arg-Gly-Asp) cell binding sequence in the 
type III module of FN (168, 169). In addition to cell surface integrins, FN also binds 
other ECM components such as collagen (170), glycosaminoglycans (171), and fibrin 
(172). 
Utilizing platelet purified and recombinant CD9, Longhurst et al, 2002 reported 
that CD9 can interact with human plasma FN (129). Experimental evidence based on 
whole cell assays implicates that EC2 region of CD9 is important in binding to FN. 
Experiments performed with FN fragment suggest that CD9 preferentially interacts with 
the 40 kDa fragment of FN that includes heparin-binding domain Hep-2 and the IIICS 
domain but not with the 120 kDa fragment that contains the cell attachment domain with 
RGD amino acid motif (173).  
Pregnancy specific glycoproteins (PSG) are members of the carcinoembryonic 
antigen (CEA) family of proteins synthesized by the placenta (174). Secreted specifically 
during pregnancy, PSG family of proteins induces cytokine production by the 
monocyte/macrophage cells (175). PSG17 is the first soluble ligand that was reported to 
bind CD9 (176). Baculovirus expressed recombinant PSG17 was shown to selectively 
bind CD9 expressing cells but not CD151, CD81, CD82 expressing cells (176). Also, 
anti-CD9 mAbs specifically inhibited CD9 interactions with PSG17 suggesting that 
CD9/PSG17 binding is a direct cis interaction (177). 
Ha et al, 2005 subsequently reported that binding of murine PSG17 to CD9 on 
monocytes can induce the production of anti-inflammatory cytokines such as IL-10, IL-6, 
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and TGF-β1 (178). Interestingly, mutations in CD9 regions required for sperm-egg fusion 
(amino acids: 173-175) also appear to be essential for PSG17-CD9 interaction (177).  
Interleukins are molecules secreted by immune cells that mediate inflammatory 
response (179). Interleukin 16 (IL-16) is a lymphocyte chemo attractant that is a well 
established ligand for CD4 (180, 181). IL-16 is produced by variety of cells and acts as a 
major chemotactic stimulus for CD4 positive T-lymphocytes. Mast cells are components 
of connective tissue that participate in normal as well as abnormal immune response. 
Mast cells express high levels of tetraspanin CD9 but do not express CD4. Qi et al, 2006 
reported that mast cell CD9 can serve as an accessory receptor for the IL-16 (182). IL-16 
mediated chemotactic response of mast cells was blocked by anti-CD9 mAbs and IL-16 
was shown to directly bind to CD9 expressing CHO cells.  
The common feature of CD9 binding ligands is their ability to interact with the 
EC2 domain. Most of the monoclonal antibodies raised against CD9 bind the EC2 region 
of CD9, which explains the ability of these reagents to characteristically modulate CD9 
mediated cellular effects. Additionally, synthetic peptides and recombinant proteins from 
the EC2 region also have profound effects on CD9 induced phenotypic changes. 
 
1.11 CD9 and Signal Transduction Pathways 
Signal transduction events mediate cellular responses to environmental cues. 
Signal transduction pathways are initiated by specific extracellular stimuli generated via 
cell surface molecules. For example, adhesion molecules such as integrins transduce 
intracellular signals upon engagement with the extracellular matrix components during 
cell adhesion (183). Recognition of extracellular stimuli by cells leads to activation of 
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specific intracellular enzymes known as kinases. The final effect of signal transduction 
pathways such as regulation of gene transcription and cytoskeletal changes largely 
depend upon the type of signaling pathway that is activated in a cell.  
The earliest evidence demonstrating the ability of CD9 to affect intracellular 
signaling events came from studies in human platelets, where anti-CD9 mAb, ALB6, was 
shown to induce calcium influx in platelets (111). Subsequently, several groups have 
reported a similar finding, where several other anti-CD9 mAbs were also shown to elicit 
Ca2+ influx in platelets (184, 185). Anti-CD9 mAbs have also been shown to activate p72 
Syk in platelets (186), and enhance phosphoinositide turnover (102).  
Evidence of CD9 participation in signal transduction pathways is not limited to 
anti-CD9 perturbation studies, as it has been shown that expression of CD9 in cultured 
cells can also modulate intracellular signaling. Shaw et al, 1995 showed that ectopic 
expression of CD9 in Burkitt’s lymphoma cell line, Raji, induced tyrosine 
phosphorylation of several proteins in adhesion dependent manner (28). Klein-Soyer et 
al, 2000 have shown that adhesion of cultured endothelial cells to the anti-CD9 mAb 
coated substrata also induced protein tyrosine phosphorylation (91).  
As with the CD9-integrin interactions, CD9 mediated signaling events also appear 
to be highly cell type specific as CD9 can activate a multitude of intracellular signal 
transduction pathways. This in part can be explained by the variations in the composition 
of the “tetraspanin web” from one cell to another (187). Table 1.5 summarizes the list of 
various signal transduction pathways that have been reportedly modulated by CD9. 
Anti-human CD9 mAb, ALB-6, was shown to induce apoptosis in tumor cells 
(188). Shc is an adapter protein that upon tyrosine phosphorylation activates multiple 
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intracellular signaling pathways (189). In the gastric cancer cell line, MKN-28, treatment 
of cells with ALB-6 antibody enhanced tyrosine phosphorylation of p46 isoform of Shc, 
an event that lead to activation of c-Jun NH2- terminal kinase/stress-activated protein 
kinase (JNK/SAPK) and the p38 MAPK pathways.  
JNK/MAPK pathways are activated on expression of CD9 in human melanoma 
cells (190). In melanoma cells, expression of CD9 was shown to induce matrix 
metalloprotenase-2 (MMP-2) expression in a JNK/p38 MAPK dependent manner (190). 
Other components of MAPK pathway are reportedly activated by CD9. For example, 
using anti-CD9 perturbation, p44/42 MAPK but not p38MAPK was shown to be 
important in CD9 dependent osteoclast differentiation (136).  
Wnt signaling pathway is essential for normal cellular development and mutations 
of molecules in this pathway are implicated in several cancers (191). Expression of CD9 
in tumor cell lines HT1080 and A549 was shown to downregulate expression of Wnt 
family of proteins Wnt1, Wnt2b1 and Wnt5a (192) and the Wiskott-Aldrich syndrome 
protein (WASP), WAVE-2 (193). Expression of CD9 in HT1080 cells also altered the 
subcellular localization of the cytoskeleton modifying proteins Arp2 and Arp3 which 
was dependent on WAVE-2 but not Wnt members (193). The functional significance of 
Wnt signaling pathway in CD9 mediated cellular effects remains to be addressed. 
In addition to the above reported observations, CD9 and other tetraspanins were 
shown to associate with the lipid kinase, phosphatidylinositol-4 kinase (PI-4K) ((20). 
Although this finding suggests that tetraspanins may recruit PI-4K to the membrane 
proximal regions, the biological relevance of this association is not known. Focal 
adhesion kinase (FAK) is both phosphorylated and activated downstream of integrins 
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Table 1.5 Intracellular Signaling Pathways Modulated by CD9 
 
Molecule Cells Effects 
PI-4 Kinase - - 
P46Shc Cancer Cells  
Wnt1, Wnt2b1 
and Wnt5a 
Fibrosarcoma 
Cells 
- 
P44/42 MAPK Osteoclasts Osteoclastogenesis 
P38 MAPK Melanoma Cells Regulates Matrix 
Metalloprotease 
Expression 
FAK Vascular Smooth 
Muscle Cells 
Cell Motility 
WAVE-2 Fibrosarcoma Cells Cell Motility 
Ca2+ Platelets Platelet Activation and 
Aggregation 
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leading to stimulation of other intracellular signaling pathways such phosphatidylinositol-
3 kinase (PI-3K) (194). In vascular smooth muscle cells, CD9 was shown to modulate 
tyrosine phosphorylation of FAK (92).  
Based on the above observations, the following conclusions can be drawn with 
regard to overall role of CD9 in signal transduction pathways. Since most of the reports 
utilize mAbs to interfere with CD9’s function and because mAbs can be either 
stimulatory or inhibitory in nature, it is unknown whether CD9 is actually stimulatory or 
inhibitory with respect to specific signaling pathways. The findings also suggest that in a 
given cell, CD9 has the potential to modulate multiple signaling pathways. Also, it is 
unclear whether important CD9 mediated biological phenomenon such as cell migration 
directly depends on these signaling pathways. 
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Chapter 2: Study Objectives
 
2.1 Background 
CHO cells were originally described as an in vitro model system for their unique 
characteristic of genomic stability in long-term culture (195). Since then researchers have 
extensively used CHO cells as a model system for characterizing a variety of novel 
proteins (196-199). The effects of stable expression of human CD9 on CHO cell 
phenotype have been thoroughly characterized and documented in our laboratory. The 
major phenotypic changes induced on expression of human CD9 in CHO cells include 
altered cell morphology, spreading, adhesion, haptotactic cell motility, and pericellular 
FN matrix assembly (129, 173, 182, 200).  
Morphologically CD9- CHO cells are very distinct from the Mock transfected 
cells (Mock-CHO) (173). CD9- CHO cells appear as polygonal shaped cells as opposed 
to characteristic spindle shape of Mock-CHO cells or the naïve CHO cells. In addition, 
CD9-CHO exhibited significantly increased cell spreading on FN (173) when compared 
to Mock-CHO cells. Comparative analysis of the CD9 induced spread phenotype on 
fragments of FN showed that a 40 kDa fragment of FN that includes the HEP2/IIICS 
regions was sufficient to induce this phenotype (173). 
Another significant phenotypic change induced in CHO cells upon expression of 
human CD9 is upregulation of haptotactic cell motility on FN (129). In vitro Transwell 
migration assays showed that CD9-CHO cells had a 3-4 fold higher migration rate than 
Mock-CHO cells. The promigratory effect of CD9 was specific for FN and was not seen 
with other extracellular matrix proteins such as fibrinogen (FG) (129). 
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To define the critical regions on CD9 required for enhanced cell migration on FN, 
CHO cell lines expressing CD9 truncation mutants in the EC2 region were generated 
(129, 173, 200). Analysis of these cell lines showed that the EC2 region was sufficient 
and necessary for promoting cell migration on FN (129). Furthermore, a peptide 
corresponding to the EC2 region (a.a 168-192) blocked CD9 induced haptotactic cell 
motility on FN (129). Similarly, recombinant fragments corresponding to the CD9 EC2 
region were also shown to inhibit transendothelial migration of leukocytes (90). Also, as 
mentioned earlier both bacterially expressed and platelet purified CD9 were able to bind 
purified FN (129).  
In addition to profoundly influencing cell spreading and cell motility, CD9 
expression also modulates the extent of pericellular FN matrix assembly in CHO cells 
(173). As seen in studies of haptotactic motility, the EC2 region of CD9 was shown to be 
critical for modulating pericellular FN matrix assembly in CHO cells. These studies 
demonstrated that CD9 modulated adhesive phenotypes in which integrin α5β1 directly 
participates. CHO cells express the integrin α5β1 endogenously where it acts as the 
primary FN receptor (147). Interestingly, a function blocking mAb specific for hamster 
α5β1 abolished CD9 induced CHO cell spreading on FN (201). 
Cumulatively, these earlier studies suggest that CD9 acts in concert with α5β1 to 
influence adhesive cell phenotypes in response to FN. The precise molecular mechanisms 
of potential CD9-α5β1 cooperation are as yet unclear and are a subject of current 
investigation. Both CD9 and integrin α5β1 can activate intracellular signaling pathways. 
Integrin mediated signal transduction events driving cell motility have been well 
characterized and documented (202). In contrast, the influence of CD9 on signal 
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transduction pathways responsible for specific adhesion dependent cell phenotypes still 
remains elusive. In order to address these previously unanswered questions, our current 
study aims to gain insight into novel aspects of CD9 biology. 
 
2.2 CD9 Mediated Signaling Pathways in Cell Motility 
In order to gain insight into the molecular mechanisms of CD9 mediated cell 
motility, one of our objectives was to investigate the intracellular signal transduction 
pathways involved in CD9 mediated haptotactic cell motility. Given the complexity of 
CD9-integrin interactions, a wide range of intracellular signaling pathways emerge as 
potential candidates for CD9 mediated cell migration. For example, activation of 
adhesion molecules can activate a number of intracellular kinases such as MAPK (203), 
PI-3K (204), and focal adhesion kinase (FAK) (194) that are important regulators of cell 
motility. Adapter proteins such as p130Cas have also been shown to modulate cell 
motility downstream of integrins (205) and kinases such as PKC have been reported to 
associate directly with tetraspanins (38). 
In this study, we systematically examined the role of several of these candidate 
molecules in CD9 mediated haptotactic cell motility to FN. A number of cell permeable, 
small molecule inhibitors are available to target these signaling molecules in a highly 
specific manner. The first approach was to test the effects of these compounds in CD9 
mediated haptotactic cell motility. Where possible, molecular strategies such as 
dominant/negative transfections, siRNA mediated gene silencing will be employed to 
further define the role of individual signaling pathways responsible for CD9 mediated 
cell motility.  
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2.3 Role of Integrins in CD9 Mediated Cell Motility 
Since, CD9 and other tetraspanins participate in extensive lateral interactions with 
integrins (137), CD9 may play a role in the regulation of integrin conformational states. 
Information regarding the ability of tetraspanins to participate in mechanisms modulating 
integrin conformation is limited. Recent studies have shown that tetraspanin CD151 can 
stabilize the active conformation of integrin α3β1 (206). CD9 complex with platelet 
GPIIb/IIIa has been shown to be dependent upon the conformational state of GPIIb/IIIa 
(110). Although CD9 associates with integrin β1, it is not known whether CD9 can 
modulate β1 conformation states.   
Integrins exist in two different conformational states (25, 207, 208). Based on 
structural studies, it has been hypothesized that the head domain of integrins can exist in 
a bent conformation that extends upon ligand binding. Also, integrin mediated cellular 
effects are thought to directly correlate with the active conformation of the molecule 
(209, 210). In addition to the ligand binding, integrins can be activated by divalent 
cations such as Mn2+ and Ca2+ (211-213). 
Therefore, the second major focus of the study was to explore CD9 interactions 
with integrins and to study the possible role of CD9 in modulating integrin conformation. 
Using cultured cells and platelets as model systems, we investigated CD9 interaction with 
β1 and β3 integrins. We also proposed to examine the physical relationship between CD9 
and α5β1. Additionally, the functional significance of CD9-α5β1 interactions in CD9 
mediated haptotactic cell motility was investigated with the available function blocking 
mAbs. Finally, we aimed to determine the role of CD9 in modulation of β1 integrin 
conformation and activation. 
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Figure 2.1 is a schematic representation of the potential signal transduction 
mechanisms that are implicated in CD9 mediated cell motility. In summary, modulation 
of integrin conformation and therefore function by CD9 can regulate intracellular signal 
transduction cascades emanating from cell-ECM ligand interactions. The proposed 
signaling molecules (PI-3K, PKC, MAPK, p130Cas, and FAK) under investigation have 
been well documented to participate in adhesion molecule mediated signal transduction 
cascades. 
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Figure 2.1 Hypothesized Mechanisms of CD9 Mediated Cell Migration 
 
PLC: Phospholipase C, DAG: Diacyl glycerol, IP3: Inositol 3 phosphate, PKB: Protein 
kinase B, RGD: Minimal domain in ECM proteins that binds integrins, α, β: Subunits of 
functional integrin molecule, FAK: Focal adhesion kinase, MAPK: Mitogen-activated 
protein kinase, PI-3K: Phosphatidylinositol-3 kinase, Y: Tyrosine residue of signaling 
molecules. 
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Chapter 3: Experimental Procedures 
 
3.1 Antibodies and Reagents 
All the chemical reagents, unless otherwise specified, were purchased from 
Sigma-Aldrich (St. Louis, MO). Human plasma FN, RPMI, DMEM, Trypsin-EDTA and 
geneticin were obtained from Invitrogen (Carlsbad, CA). Pharmacological inhibitors 
wortmannin, LY294002, GÖ6976, and PD98059 were purchased from Calbiochem (San 
Diego, CA). The monoclonal anti-CD9 antibody, mAb7, has been described previously 
(109). Anti-rat CD9 (RPM.7), anti-mouse CD9 (KMC.8) and anti-rat α5 (HMα5-1) 
antibodies were from BD Pharmigen (San Diego, CA). Anti-human β1 integrin mAb 
(TS2/16) was a kind gift from Dr. Xin Zhang. 
Anti-integrin β1 (Clone-B44), and anti-actin mAb (clone C4) were purchased 
from Chemicon International (Temecula, CA). Anti rat-β1 (HMβ1 -1), hamster IgG 
isotype control, and goat anti-hamster FITC antibodies were from Biolegend (San Diego, 
CA).  Monoclonal antibodies against platelet GPIIb/IIIa complex (10E5, C3) and IIIa or 
β3 (AP3) and have been previously described (214, 215). The mAb 10E5 was a gift from 
Dr. Barry Coller and AP3 was kindly provided to us by Dr. Peter Newman. Anti-human 
β1 integrin antibody that reacts with rat β1 integrin (clone-18), anti-p130Cas mAb (clone 
21), anti-focal adhesion kinase mAb (clone 77/FAK) and horseradish peroxidase (HRP) 
conjugated anti-phosphotyrosine (Clone-RC20) mAbs were from BD Transduction 
Laboratories (San Diego, CA).   
Rabbit polyclonal anti-α5 antibody (H-104), anti-CD9 antibody (C-4), anti-β3 (C-
10), p130Cas siRNA duplex and the control siRNA duplex were from Santa-Cruz 
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Biotechnology (Santa Cruz, CA). Anti-rat α1 (clone 3A3), and anti-rat β3 (clone F11) 
antibodies were from Serotec (Oxford, UK). Anti-phospho Akt S473 (9271s) and total 
Akt (9272) antibodies were from Cell Signaling (Beverly, MA). Anti-hamster α5β1 
(PB1) was purchased from Developmental Studies Hybridoma Bank (Iowa City, IA). 
Rabbit polyclonal anti-PI-3K (p85) antibody was from Upstate Biotechnology (Lake 
Placid, NY). Anti-GFP antibody (JL-8) and BD-Adeno-X virus purification kit were 
purchased from BD Biosciences (Bedford, MA). The PI-3K dominant/negative plasmid 
(∆p85) was a kind gift from Dr. Larry Pfeffer. 
Transwell polycarbonate filters (8.0 µm pore size) for migration assays were 
purchased from Nunc International (Rochester, NY). Permount solution was purchased 
from Fisher Scientific. All the secondary antibodies for Western blot and the ECL 
substrate kits were from Amersham Biosciences (Piscataway, NJ). Protein G-Plus 
Protein-A agarose beads were from Oncogene (San Diego, CA). Non fat dry milk 
(NFDM) was purchased from Nestle. RestoreTM Western blot stripping buffer was 
purchased from Pierce (Rockford, IL).  
 
3.2 Cell Culture Methods 
The Chinese hamster ovary cell line CHO-K1, purchased from American Type 
Culture Collection (ATCC) was used for these studies. Mock transfected CHO (Mock-
CHO) cells and a stable clone of CD9-CHO (A6) cells have been previously described 
(200). Mock and A6 cells were routinely cultured in RPMI-1640 medium supplemented 
with 10% fetal bovine serum (FBS) and 0.75 mg/ml of the selection agent Geneticin 
(RPMI Growth Medium). 
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Smooth muscle cells isolated from thoracic aortae of Sprague-Dawley rats by 
enzymatic dissociation were provided to us by Dr. Gadiparthi N. Rao. Isolated smooth 
muscle cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 10%FBS, 100 units/ml of penicillin and 100 µg/ml of streptomycin 
(DMEM Growth Medium). After expansion, cells were frozen in liquid nitrogen in the 
DMEM medium containing 20% FBS and 10% dimethyl sulfoxide (DMSO). For culture, 
the frozen vial of cells are quickly thawed and added to culture dish containing 
prewarmed DMEM Growth Medium.  Mouse embryonic fibroblasts (MEF) and Human 
embryonic kidney (HEK-293) cells were purchased from ATCC and were cultured in 
DMEM Growth Medium as described above.  
The human fibrosarcoma cell line (HT1080) was cultured in DMEM Growth 
Medium. For generation of CD9 stable transfectants of HT1080 cells, the following 
protocol was used. Approximately 2.5X107 HT1080 cells suspended in 300 µl of ice cold 
phosphate buffered saline (PBS) were mixed with 50 µg of pRc/CMV plasmid containing 
human CD9 cDNA (77) and incubated on ice for 10 min. Pulse electroporation was 
performed at 0 Ohms, 300 V and 950 µF setting and immediately after electroporation; 
cells were transferred onto ice and rested for 10 min at room temperature.  
The electroporated cells were transferred into culture flasks containing DMEM 
supplemented with 10% FBS and incubated in humidified CO2 incubator at 37oC. 
Electroporation with empty vector (pRc/CMV) were similarly performed to generate 
Mock-HT1080 cells. Since pRc/CMV plasmid contained G418 as a eukaryotic selection 
marker, 48 hrs after transfection, the culture medium was supplemented with 0.75 mg/ml 
of Geneticin. Successful expression of CD9 in the transfected cells was confirmed by 
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flow cytometry (FCM) with a monoclonal antibody specific for CD9 (mAb7). 
Subsequently, the population of cells with highest expression of human CD9 (top 5%) 
was sorted by fluorescent-labeled cell sorting using mAb7. 
 
3.3 Flow Cytometry 
FCM was routinely performed to detect the surface expression of CD9 on A6 
cells. For these experiments, confluent Mock or A6 cells were seeded at a density of 
2.5Χ106 cells/ 75 cm2 flask 24 hrs prior to FCM. Twelve to eighteen hrs after seeding, 
cells were harvested by trypsinization for 2 min at 37oC and counted by trypan blue 
exclusion. Cells were then suspended in RPMI labeling media (RPMI-1640 containing 
5% goat serum) as 5Χ105 cells/ml and incubated on ice for 1 hr. Cells were subsequently 
incubated in the primary antibody (mAb7; 4 µg/ml) for 1 hr on ice. The unbound 
antibody was removed by washing the cells three times with ice cold PBS and cells were 
incubated in the secondary antibody diluted in labeling media (goat-anti-mouse FITC 
conjugate; 5 µg/ml) for 1 hr on ice. After secondary antibody incubation, cells were 
washed 3 times in PBS and suspended in 0.5 ml of PBS and data were acquired using 
FACS Calibur flow cytometer (Becton-Dickinson, Mountain View, CA) equipped with 
Cell Quest Pro software. 
For FCM analysis utilizing the adenoviral transduced Rat Aortic Smooth Muscle 
(RASM) cells, experiments were performed 72 hrs after transduction. Briefly, adenoviral 
transduced RASM cells were harvested by trypsinization for 1 min at 37oC and the 
harvested cells were suspended in DMEM labeling medium (DMEM containing 5% goat 
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serum) for 1 hr on ice. Subsequent steps for primary, secondary antibody incubation and 
data analysis were performed as described above.  
For FCM experiments performed for the detection of active conformation of β1 
integrin, the following procedure was used. Lyophilized integrin activating peptide 
RGDS and the negative control peptide RGES were reconstituted in PBS and 10 mM 
stock solutions were aliquoted and stored at -80oC. Mock or A6 cells were cultured as 
described above. Harvested cells were suspended in RPMI labeling media as 5Χ105 
cells/ml and incubated for 1 hr on ice.  
In order to activate β1 integrin, cells were incubated with 1 mM RGDS or RGES 
peptides for 30 min at 37oC. Subsequent to activation of integrin with the peptides, cells 
were incubated with the 5 µg of β1 integrin conformation sensitive antibody (B44) and 
incubated on ice for 45 min. The unbound antibody was removed by washing cells three 
times with PBS and the cells were incubated with goat anti-mouse-FITC (GAM-FITC) 
conjugated secondary antibody. Cells were further processed as described in the earlier 
sections. 
 
3.4 Immunoprecipitation and Western Blot Analysis of Platelet Antigens 
All the steps for platelet isolation were carried out at room temperature. Venous 
blood was drawn from healthy, consented adult volunteers in to anticoagulant ACD (85 
mM sodium citrate, 100 mM dextrose, 70 mM citric acid, pH 4.6) and platelet-rich plasma 
(PRP) was separated by centrifugation at 100Xg for 20 min. Platelets were further 
isolated from PRP by centrifugation at 800Xg for 10 min. The isolated platelets were 
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gently resuspended in a buffer containing 10 mM sodium citrate, 30 mM dextrose and 
120 mM sodium chloride, pH 6.5 (CGS buffer).  
Platelets were washed twice in CGS buffer prior to lysis in Brij-98 lysis buffer 
(Table 3.1). Platelet proteins were solubilized in the Bri-98 lysis buffer for 20 min at 4oC 
and the resulting lysates were clarified by centrifugation at 14,000 rpm for 10 min at 4oC 
and protein concentration was determined using the detergent compatible Dc protein assay 
kit (Bio-Rad, Hercules, CA). 
For IP, lysate volume equivalent to 2 mg protein for each sample was made to 1 
ml with Bri-98 lysis buffer. For preclearing, samples were incubated with 75 µl of protein 
A plus protein G agarose beads with agitation for 1 hr at 4oC. Lysates were then 
centrifuged at 14,000 rpm for 1 min, beads discarded and the supernatants were 
transferred in to fresh tubes. The precleared lysates were then incubated with 5 µg of the 
mAb specific for the platelet antigen (Table 3.2) and incubated for 1 hr at 4oC on IP 
rocker.  
As a negative control, lysates were also incubated with the isotype-matched mAb 
(MOPC-21). Immune complexes were captured by incubating with 75 µl of protein A 
plus protein G agarose beads for 1 hr at 4oC with agitation. The beads were washed 3-4 
times with the Brij-98 lysis buffer, and after the last wash, 20 µl lysis buffer was left with 
the beads. Immune complexes were eluted from the beads by boiling the samples in 
Laemmli sample buffer for 10 min.
The eluted proteins were resolved on 5-20% gradient of sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE). For Western blot analysis, proteins were transferred 
onto Immobilon-P membrane (Millipore, Billerica, MA) by electro-elution at a constant 
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Table 3.1 Composition of Brij-98 Lysis Buffer 
 
Reagent Stock Final 
Brij-98 10% 1% 
Hepes 1 M 10 mM 
NaCl 3 M 200 mM 
MgCl2 1 M 5 mM 
NaF 0.5 M 2 mM 
Na4P2O7 100 mM 10 mM 
Na3VO4 200 mM 200 µM 
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Table 3.2 Antibodies Used for the Characterization of CD9-GPIIb/IIIa Complex 
 
 
Platelet Antigen Antibody for IP Primary Antibody 
(Dilution) 
Secondary Antibody 
(Dilution) 
GPIIb/IIIa 10E5 Anti-GPIIb, C-3 
(1:10,000) 
SAM-HRP 
(1:50,000) 
β3 integrin AP3 Anti-β3, C-20 
(1:500) 
MAG-HRP 
(1:50,000) 
CD9 mAb7 Anti-CD9, C-4 
(1:500) 
SAM-HRP 
(1:5,000) 
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current setting of 700 mAmp. After the transfer, membranes were blocked for 6 hrs at 
4oC in TBST (20 mM Tris, 200 mM NaCl, 0.1% Tween-20) containing 5% non-fat dry 
milk (NFDM). Further to this, blots were incubated in primary antibody diluted in 
TBST/5% NFDM for 12-18 hrs at 4oC.  
The unbound antibody was removed by washing the blots (5 times) with TBST 
for 10 min at room temperature. After the final wash, the membranes were incubated in 
the secondary antibody solution for 1 hr at room temperature. Finally, membranes were 
washed 5 times (10 min/wash) in TBST and developed with enhanced 
chemiluminescence (ECL) substrate. Table 3.2 shows the list of antibodies and their 
dilutions used for Western blot analysis of the platelet antigens. 
 
3.5 Generation and Purification of CD9-Adenovirus 
The E1 region deleted adenoviral shuttle vector and pacAd5 9.2-100 plasmid were 
kindly provided to us by Dr. Aviv Hassid. Using these reagents, recombinant adenovirus 
expressing human CD9 (Ad-CD9) was generated as follows. The EcoR1 and Xba1 
double digested fragment containing full-length human cDNA gene was excised from the 
plasmid pRc/CMVp24/CD9 (77) and was subcloned into EcoR1 and Xba1 sites of E1 
deleted adenoviral shuttle vector. The resulting adenoviral shuttle vector was co-
transfected into HEK293 cells with pacAd5 9.2-100, an adenoviral type5 backbone 
genome plasmid to generate Ad-CD9 by in vivo recombination. The Ad-CD9 construct is 
a replication-deficient, recombinant adenoviral vector capable of expressing full-length 
human CD9.  As a negative control for transduction experiments, adenovirus containing 
LacZ gene (Ad-LacZ) was generated as described earlier (216).  
 55
For purification, adenovirus was amplified in a E1 complementing HEK 293 cell 
line with a BD-Adeno-X virus purification kit according to the manufacturer’s protocol. 
Briefly, low passage number HEK-293 cells cultured in DMEM medium supplemented 
with 10% FBS. The cells were infected for 90 min with the stock virus at a virus 
concentration of one multiplicity of infection (MOI). MOI is defined as a ratio between 
numbers of infectious virus particles to the number of target cells. After typical 
cytopathic effect (cells detach from the substratum and form grape like clusters) was 
observed, cells were harvested, and virus was purified utilizing a BD-Adeno-X virus 
isolation kit. After purification, adenoviral stock solutions were aliquoted and stored at -
80oC for future use. The titer for the virus was estimated by soft-agar plaque assay as 
described previously (216).  
For the transduction of rat aortic smooth muscle cells (RAMS), cells were first 
grown to ∼80% confluence in 10 cm culture dishes. The volume of Ad-CD9 or Ad-LacZ 
virus stock solutions equivalent to 100 MOI was diluted in 1 ml DMEM medium. The 
RASM cell growth media was removed, and replaced with 1ml of the virus solution in 
DMEM medium dropwise. The infected cells were then incubated at 37oC in 5% CO2 
humidified incubator for 90 min with manual rocking every 15 min. Negative control 
RASM cells treated with 1ml of DMEM alone. After 90 min post infection, the culture 
were supplemented with 9 ml of DMEM medium and returned to the incubator. 
Subsequent analysis of cells was done at 72 hrs post infection. 
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3.6 Immunoprecipitation and Western Blot Analysis of Cultured Cells 
For HT1080 cells and the MEF, culture monolayer’s were washed two times with 
ice cold PBS (10 ml/dish for each wash) to remove the traces of fetal bovine serum 
(FBS). The cells were then scraped into Brij-98 lysis buffer and proteins were solubilized 
for 20 min at 4oC.  The resultant lysates were clarified by centrifugation at 14,000 rpm 
for 10 min at 4oC and supernatants were transferred into fresh tubes and were stored at -
80oC.  
For IP of proteins from MEF cell lysates, 1 mg protein for each sample was made 
to 1 ml with Bri-98 lysis buffer.  The lysates were then incubated with 5 µg anti-CD9 
(KMC.8), anti-α5 (HMα5-1), and anti-β1 (HMβ1-1) mAbs for 1 hr 4oC with agitation. 
As a negative control, lysates were incubated either with rat IgG (isotype control for 
KMC.8) or the hamster IgG (isotype control for HMα5-1, HMβ-1). Subsequently, 
immune complexes were captured with 75 µl of protein A plus protein G agarose beads 
for 1 hr at 4oC with agitation. The beads were washed 3-4 times with the Brij-98 lysis 
buffer, and after the last wash, 20 µl lysis buffer was left with the beads. Immune 
complexes were eluted from the beads by boiling the samples in Laemmli sample buffer 
for 10 min.  
The eluted proteins were resolved on 5-20% SDS-PAGE and Western blot was 
performed as described above. The presence of α5 in the immunoprecpitates was 
detected with a polyclonal antibody against α5. IP experiments with HT-1080 cells were 
essentially performed by similar protocol except that mAb7 and TS2/16 antibodies were 
used to immunoprecipitate CD9 and β1, respectively. 
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For IP experiments RASM cells were lysed in Brij-98 lysis buffer. For each IP 
reaction, 1 mg of lysate was precleared with protein-G plus protein-A agarose beads for 1 
hr at 4oC. Targeted proteins from precleared lysates were immunoprecipitated with 5 µg 
of antigen specific mAb and the respective isotype matched control mAbs.  
Immunecomplexes were washed four times with Brij-98 lysis buffer and samples were 
boiled in Lammeli sample buffer before loading onto 5-20% SDS-Page. Subsequent 
analysis of proteins by Western blot was carried out as described above. Table 3.3 
summarizes the list of antibodies used in these experiments.  
 
3.7 Determination of Akt Phosphorylation 
Whole cell lysates were prepared from cultured cells either held in suspension or 
plated on to FN coated culture dishes. For coating, four ml of 10 µg/ml human plasma 
FN was added to 10 cm culture dishes for 3 hrs at 37oC. The FN solution was removed 
and non-specific binding sites were blocked with 5 ml phosphate buffered saline (PBS; 
pH 7.4), 5% Bovine serum albumin (BSA). Harvested cells were suspended in the basic 
culture medium (RPMI for CHO cells, DMEM for RASM) supplemented with 1% BSA. 
Mock and CD9-CHO (A6) cells or the transduced RASM cells (Ad-CD9 and Ad-LacZ) 
and untransduced control cells were plated onto FN coated culture dishes at 2.5x106 
cells/dish and allowed to adhere for indicated time.  
All the incubations were carried out in a humidified 5% CO2 incubator at 37oC. 
Control cells were held in suspension in RPMI or DMEM + 1% BSA at 37oC. After 
adhesion, cells were washed two times in ice-cold PBS and lysed in Triton-X100 lysis 
buffer (Table 3.4). Protein concentration in the samples was determined by Biorad Dc 
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Table 3.3 Antibodies Used for the Detection of CD9-α5β1 Complex 
 
Antigen Antibody for IP Primary Antibody 
(Dilution) 
Secondary Antibody 
(Dilution) 
α5 integrin HMα5-1 Anti-α5, H-104 
(1:2,500) 
DAR-HRP 
(1:25,000) 
β1 integrin HMβ1-1 Anti-β1, Clone-18 
(1:1,000) 
SAM-HRP 
(1:25,000) 
CD9 mAb7 Anti-CD9, C-4 
(1:500) 
SAM-HRP 
(1:50,000) 
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Table 3.4 Composition of Triton-X 100 Lysis Buffer 
 
 Reagent Stock Final Concentration 
Tris 1 M 20 mM 
NaCl 3 M 150 mM 
Deoxycholate 10% 0.5% 
SDS 10% 0.1% 
Triton-X 100 10% 1% 
EDTA 500 mM 5 mM 
Protease Inhibitor Cocktail 100% 1% 
Phosphatase Inhibitor Cocktail-I 100% 1% 
Phosphatase Inhibitor Cocktail-II 100% 1% 
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protein assay kit and lysate equivalent to 40 µg of protein was boiled with Laemmli 
buffer for 10 min. The proteins were then resolved on SDS-PAGE and transferred onto 
Immobilon-P membrane as described above. 
For Western blot analysis, membranes were first blocked for 6 hrs at 4oC in TBST 
solution containing 5% BSA. The blots were then incubated for 12-18 hrs at 4oC in the 
primary antibody solution and the unbound antibody was removed by washing the blots 
with TBST. Subsequently, blots were incubated in horseradish peroxidase (HRP) 
conjugated donkey anti-rabbit (DAR) secondary antibody for an hr followed by washing 
the blots five times with TBST. Subsequently, the bands were developed with ECL 
substrate. As a loading control, the cut portions of the blots containing 40 kDa actin 
bands were probed with mAb specific for actin (Chemicon, mAb 1501).  
After analyzing the blots for phosphorylated Akt, the antibodies were removed 
with Restore Western blot stripping buffer. The membranes were incubated in Restore 
buffer for 15 min at 37oC with continuous agitation followed by manual rocking for 5 
min. The blots were then washed with TBST and incubated in blocking buffer containing 
TBST and 5% non fat dry milk. The membranes were then reprobed for total Akt with a 
polyclonal antibody (9272) against Akt. Table 3.5 shows the concentrations of various 
antibodies used in these experiments for Western blot analysis. 
 
3.8 Determination of Protein Tyrosine Phosphorylation 
Mock and A6 cells were seeded onto FN coated culture dishes as described above. 
The cells were allowed to adhere for indicated time in a humidified 5% CO2 incubator at 
37oC. Control cells were held in suspension in RPMI + 1% BSA at 37oC. Whole cell  
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Table 3.5 Antibodies Used for the Western Blot Analysis of CHO Cell Lysates 
 
Antigen Primary Antibody 
(Dilution) 
Secondary Antibody 
(Dilution) 
p130Cas 
 
Anti-p130Cas 
(1:1,000) 
SAM-HRP 
(1:25,00) 
FAK Anti-FAK 
(1:1,000) 
SAM-HRP 
(1:1,000) 
Actin 
 
Anti-CD9, C-4 
(1:25,000) 
SAM-HRP 
(1:50,000) 
Akt S473 
 
Phospho Akt (9271s) 
(1:1,000) 
DAR-HRP 
(1:25,000) 
Akt 
 
Total Akt (9272) 
(1:1,000) 
DAR-HRP 
(1:25,000) 
Phospho Tyrosine 
 
RC-20 HRP 
(1:2,500) 
- 
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lysates were prepared with Triton-X100 lysis buffer and protein concentration was 
estimated as described earlier. Lysate volume equivalent to 40 µg for each sample was 
resolved on SDS-PAGE. For Western blot analysis, blots were blocked in TBST+5% 
BSA and incubated with HRP conjugated anti-phosphotyrosine mAb (RC-20 HRP). Cell 
lysates were also analyzed for total levels p130Cas, focal adhesion kinase (FAK) and 
actin. Table 3.5 shows the concentrations of antibodies used in these experiments for 
Western blot analysis. The Western blots for FAK were developed with ECL regular 
substrate kit from Amersham Biosciences (Piscataway, NJ). 
For determining p130Cas tyrosine phosphorylation, p130Cas was first 
immunoprecipitated from 100 µg of lysates with 5 µl of anti-p130Cas mAb (clone 21) 
described above. The immune complexes were captured with 75 µl of protein G plus 
protein A beads and the captured proteins were resolved on a 7.5% SDS-PAGE. For 
Western analysis, the blots were first probed for phosphorylated tyrosine with the RC-20 
HRP antibody. For determining total p130Cas levels in the samples, the blots were 
stripped and reprobed with anti-p130Cas mAb.  
 
3.9 Transwell Migration Assays 
Haptotactic motility assays were performed using a modified Boyden chamber 
technique. For coating with FN, tissue culture inserts were placed into the wells of 24 
well culture plates added with 200 µl of 10 µg/ml human plasma FN solution and 
incubated for 3 hrs at 37oC. After incubation, excess FN solution was removed by 
blotting the edges of the inserts with absorbent paper.  
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For the motility assays in the presence of pharmacological inhibitors, cell cycle 
synchronized Mock and A6 cells were seeded in to 75cm2 flasks at a density of 2.5X106 
cells/flask. All the motility experiments were performed within 18 hrs after seeding the 
cells at this density. The inhibitor stock solutions were prepared by dissolving them in a 
solution of dimethyl sulfoxide (DMSO).  
Cells were harvested by trypsinization for 2 min, and the trypsin solution was 
neutralized and cells were suspended in RPMI-1640 medium containing 1% BSA at a 
density of 3.1X105 cells/ml and incubated for 30 min at 37oC. Where inhibitors were 
used, 2 ml suspension was removed and treated with inhibitor for 30 min at 37oC. As a 
negative control, cells were similarly treated only with the DMSO alone. FN coated 
tissue culture inserts were placed in 24 well plates containing 300 µl of RPMI+1% BSA. 
Four hundred µl of cell suspension (1.25 X105/ Insert) was added to each insert. 
Cells were allowed to migrate for 3 hrs by incubating the culture plates at 37oC in 
humidified CO2 incubator. All the samples were tested in triplicate. After the motility 
assays, the cell suspension from the tissue culture inserts was aspirated and cells adhered 
to the undersurface of the Transwell chamber were stained by placing the inserts in 24 
well plates containing 400 µl of Wright-Giemsa stain for 10 min. Four hundred µl of 
distilled water was then added to each well and staining was continued for another 10 
min.  
The inserts were then air-dried for overnight. The membranes of tissue culture 
inserts were detached carefully, placed on glass slides, and fixed with Permount solution 
and cover-slips were added. Cells from five random fields were counted under 100X 
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magnification. In each experiment, for each sample, mean cell numbers from three inserts 
were compared between different treatment groups.  
To examine the effect of serum on cell migration, Mock and A6 cells were 
initially maintained in RPMI medium containing 1% serum for 18 hrs prior to the assay. 
Subsequent steps were carried out as described above. For motility experiments 
performed with the α5β1 blocking antibody (PB1), Mock and A6 cells were treated with 
indicated concentration of PB1 for 30 min at 37oC. As a negative control for this 
experiment, an isotype matched antibody (MOPC-21) was used to pretreat the cells. For 
the migration experiments performed after transient transfections, cells were harvested 
after an indicated period after transfection and subjected to haptotactic motility assays as 
described above.  
 
3.10 Transient Transfection with Dominant/Negative PI-3K 
The ∆p85 plasmid construct, containing cDNA corresponding to 
dominant/negative p85 subunit (∆p85) of PI-3K has been described previously (217). The 
pEGFP-N1 plasmid capable of expressing a red shift variant of GFP was obtained from 
BD Biosciences. Transient transfections of Mock and A6 cells were done using 
lipofection. Optimization experiments were performed to determine the ratios of plasmid: 
lipofectamine reagent required for maximal transfection efficiency and these conditions 
were used throughout these studies. 
Twenty four hrs prior to transfection, the growth media was replaced with RPMI-
1640 containing 10% FBS (without Geneticin) and cells were transfected with 25 µg of 
plasmid DNA mixed with 25 µl of Plus reagent and 75 µl of Lipofectamine in 6 ml of 
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Optimem and cells were incubated with lipid-DNA complexes for 12 hrs. Cells 
transfected with pEGFP-N1 plasmid alone were used as negative controls. The 
transfection medium was removed and 10 ml of RPMI growth medium was added. 
Thirty-six hrs after transfection, cells were harvested for lysate preparation and 
haptotactic motility experiments. Prior to motility assays the viability of cells was 
assessed by trypan blue dye exclusion.  
 
3.11 p130Cas siRNA Transfection of CHO Cells 
All the reagents required for p130Cas siRNA transfection of cells were purchased 
from Santa-Cruz Biotechnology. As a negative control, non-specific siRNA duplexes 
were used in the transfection experiments. Lyophilized siRNA duplexes were 
reconstituted in the siRNA dilution buffer and the stock solutions were stored at -80oC for 
subsequent use. Cultured Mock and A6 cells were transfected with p130Cas siRNA 
duplex as follows.  
Cultured Mock, A6 cells were harvested by trypsinization and were seeded in 
6cm polystyrene tissue culture dishes at a density of 6X105 cells / dish. For each 
transfection, the following solutions were prepared- solution-A was prepared by adding  
24 µl of 20 µM stock solution of p130Cas siRNA duplex or the control siRNA duplex to 
300 µl of siRNA transfection medium and solution-B was prepared by adding 24 µl of 
siRNA transfection reagent to 300 µl of siRNA transfection medium. Solution-A and 
solution-B were then mixed and incubated for 30 min at room temperature. Final 
transfection medium was prepared by adding the mixture of solution-A and B to 2.4 ml 
for transfection medium. 
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At the time of transfection, cells were washed twice with 2.5 ml of RPMI 
followed by 2.5 ml of siRNA transfection medium. The final transfection mixture was 
added dropwise to the culture dishes with manual agitation. The transfected cells were 
then incubated for 6 hrs in humidified 5% CO2 incubator at 37oC when the transfection 
medium was removed and 5 ml of growth medium was added and plates returned to the 
incubator. At 24 hrs post transfection siRNA transfected cells were either lysed for 
Western blot analysis, or harvested for haptotactic motility assays. 
 
3.12 Data Analysis 
For all the motility experiments, mean cell numbers from at least three 
independent experiments were calculated and statistical significance was tested by one-
way analysis of variance (ANOVA, Boneferroni test) using Sigma Stat software package. 
Results were considered statistically significant if a p value of < 0.05 was reached. For 
quantitation of Western blot data, the following method was used. All the blots were first 
scanned and the TIFF files were exported to NIH Image software for subsequent analysis. 
For each band, representative integrated density values were computed after subtracting 
the background density. Mean integrated densities values from three independent 
experiments were calculated and their ratios with control bands were calculated using 
Microsoft EXCEL programming.  
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Chapter 4: Results and Discussion 
 
4.1 Signal Transduction Mechanisms of CD9 Mediated Cell Migration 
Cell migration is a complex phenomenon that forms the basis for several 
important biological processes such as embryonic development (218), immunity (219) 
and wound healing (220). Despite its complex nature, cell migration in organisms is 
tightly regulated and abnormal cellular migration contributes to spread of malignant cells 
from their primary site to the distant organs (tumor metastasis) (221). In addition to this, 
abnormal migration of smooth muscle cells in the vascular wall is an important 
contributing factor for the pathogenesis of vascular disorders such as atherosclerosis and 
restenosis. Cells respond to the environmental cues such as chemoattractants and growth 
factors (222) and extracellular matrix (ECM) proteins (223) via specific cell surface 
receptors. Activation of these cell surface receptors in turn leads to initiation of signaling 
pathways that ultimately affect cytoskeletal dynamics and cell migration (224).  
Integrins are heterodimeric integral membrane proteins that act as receptors to 
ECM proteins (24, 25). Integrin interactions with the ECM proteins are critical for 
maintaining the specific adhesive phenotypes of the cells. Like integrins, tetraspanins 
have also been implicated in the modulation of adhesion dependent phenomenon such as 
cell migration (137). Several lines of evidence suggest that CD9 is important in the 
regulating cell migration. CD9 expression has been shown to correlate with tumor 
metastasis (28, 115, 118, 119, 225-228) and studies using the monoclonal antibodies 
specific for CD9 have shown that CD9 modulates cell adhesion and migration on to ECM 
proteins (91, 95, 96, 121-124, 127).  
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Our earlier studies demonstrate that expression of human CD9 in CHO cells 
significantly influences haptotactic cell migration to the ECM ligand FN (129). 
Mechanistically, haptotactic cell migration involves directional migration of cells to the 
immobilized ECM proteins. Using modified Boyden chambers to perform motility 
experiments, it has been shown that expression of human CD9 in CHO cells leads to 3-5 
fold increase in haptotactic motility on to FN (129). A peptide corresponding to the CD9 
EC2 region (peptide 6; EC2 168-192) was shown to significantly inhibit CD9 promoted 
haptotactic motility to FN (129). Furthermore, analysis of CHO cells expressing CD9 
deletion mutants showed that EC2 region of CD9 is required for this phenotype (129).  
Intracellular signaling mechanisms governing CD9 mediated events are poorly 
understood. Above and beyond serving as molecular organizers, tetraspanins have been 
implicated in the transduction of adhesion dependent signals across the membrane. 
Tetraspanins CD9, CD63, CD151, and CD81 associate with PI-4K (20). Another 
tetraspanin CD82 has been shown to associate with specific isoforms of PKC (α and βII) 
and this association was shown to be independent of CD82-integrin association (38). 
Although CD9 was shown to activate multiple signaling pathways, the signaling mechanisms by 
which CD9 regulates cell motility are not known. 
In an effort to understand the molecular basis of CD9 mediated motility, we 
investigated the role of intracellular signaling molecules required for CD9 promoted 
haptotactic cell motility. To address these questions, small molecule inhibitors for 
specific signaling pathways were used in the haptotactic motility assays to initially screen 
and identify the signaling pathway responsible for CD9 promoted haptotactic cell 
migration. 
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The intracellular signaling pathways, PKC (202) MAPK (203), and PI-3K (229) 
have been previously reported to be involved adhesion molecule mediated signaling 
pathways. Pharmacological inhibitors for all these pathways are commercially available 
and are routinely being used to test the role of these pathways. Table 4.1 lists the 
pharmacological inhibitors that were used in motility experiments and the pathway/s they 
are intended to inhibit. 
The PKC is a large family of protein kinases that includes several isoforms. 
Depending on the requirement of a specific activating factor, the PKC family is further 
divided in to 3 subfamilies: classical or conventional, novel and atypical (230-232). The 
classical PKCs include α, βI, βII, γ isoforms that are activated by diacylglyerol (DAG) 
and phosphatidylcholine that are generated downstream of phospholipase C signaling 
(233-235).  
Classical PKCs have been shown to play an important role in integrin mediated 
intracellular signaling pathways (236-238). Specifically, studies have shown that PKCα 
regulates β1-integrin dependent cell motility (202). Biochemical evidence also suggests 
that TM4SF proteins including CD9 exist in complex with the activated form of classical 
PKCs (38). CD9 has been shown to exist in complex with β1 integrin in CHO cells (200). 
Therefore, we investigated the possible role of classical PKCs in CD9 mediated 
haptotactic motility.  
GÖ 6976 compound was shown to selectively inhibit classical PKCs α and β 
(239). Nanomolar (nM) concentrations of GÖ 6976 were shown to inhibit the activity of 
Ca2+-dependent isozymes of PKC in a highly specific manner (239). To study the 
contribution of PKC, PKC activity in Mock and A6 cells was inhibited with the GÖ 6976  
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Table 4.1 Inhibitors Used in CHO Cell Haptotactic Motility Experiments 
 
Serial No Compound Pathway Inhibited 
1 GÖ 6976 Protein Kinase C (PKC) 
2 PD98059 Mitogen Activated Protein Kinase (MAPK) 
3 Wortmannin Phosphatidylinositol-3 Kinase (PI-3K) 
4 LY294002 Phosphatidylinositol-3 Kinase (PI-3K) 
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compound and haptotactic motility assays were performed. Motility of Mock and A6 
cells were tested at 50 nM and 100 nM of GÖ 6976. As shown in Figure 4.1, treatment of 
Mock and A6 cells with DMSO alone did not significantly affect haptotactic motility of 
cells. Motility of Mock and A6 cells treated with two different concentrations (50 nM and 
100 nM) of GÖ 6976 were also not significantly different from respective DMSO treated 
controls. Inhibition of CD9 promoted cell migration was not observed at GÖ 6976 
concentrations as high as 14 µM (data not shown). The results suggest that suppression of 
endogenous classical PKC activity is not sufficient to inhibit CD9 promoted cell 
migration in CHO cells.  
Cell interaction with the ECM ligands activates an important intracellular 
signaling pathway known as the MAPK (203, 240). The mechanism of activation of 
MAPK involves the following steps. The first in the MAPK activation requires activation 
of receptor tyrosine kinases (RTKs) by ligand induced autophosphorylation (241). 
Phosphorylated RTKs are then recognized by src homology domain-2 (SH-2) containing 
adapter proteins such as Grb2 and Shc. Adapter proteins Grb2 and Shc recruit proteins 
like SOS subsequently leading to activation of Ras. Activated Ras further recruits and 
activates Raf-1 which directly phosphorylates and activates MEK1/MEK2. Activated 
MEK1/MEK2 phosphorylate and activates the extracellular signal regulated kinases 
(ERKs) (203). 
Integrins were reported to activate MAPK pathway by several mechanisms. 
Integrins modulate growth factor receptors (RTKs) activity thereby directly activating 
MAPK (242, 243). Integrin mediated activation of FAK and its phosphorylation on 
tyrosine (Y) 925 can also activate the MAPK pathway (244). Integrins were also reported 
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Figure 4.1 Effects of PKC Inhibitor GÖ 6976 on Cell Motility 
 
Mean cell migration of Mock and A6 cells (n=2) treated with DMSO, 50 nM and 100 nM 
of PKC inhibitor GÖ 6976. The error bars represent the standard deviation. 
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to activate the intermediate molecules of the MAPK pathway such as Raf-1 and MEK1 
(245, 246). Although the exact mechanisms are not understood both anti-CD9 mAb 
treatment and ectopic expression of CD9 were shown to regulate MAPK pathway in 
certain cell types (188, 190). 
Therefore, we examined whether CD9 mediated haptotactic cell motility requires 
MAPK pathway. Since, MEK is an upstream activator of ERK, inhibition of MEK 
activity leads to suppression of the MAP kinase pathway. PD98059 is a cell permeable 
molecule that selectively inhibits MEK1 activity thereby inhibiting MAPK pathway (247, 
248). Reported inhibitory concentration 50 (IC50) of PD98059 for different MAPK 
activators were reported to be in the micromolar (µM) range (247). To address the 
importance of MAPK pathway in CD9 induced motility, we performed motility assays at 
50 µM and 100 µM PD98059. At both the concentrations tested, CD9 enhanced motility 
was not significantly affected as compared to the respective DMSO treated controls 
(Figure 4.2). These results suggested that MAP kinase pathway may not be crucial for 
the CD9 mediated haptotaxis. 
Activation of integrins also leads to initiation of signaling through intracellular 
PI-3K (204). PI-3K is a large family of lipid kinases capable of phosphorylating the 
3rdhydroxyl group of the inositol ring of phosphatidylinositol (PI) (249). Depending upon 
the substrate specificity, PI-3K family is subdivided into 3 classes: Class I, II, and III. 
Class I PI-3K, phosphorylates PI 4, 5 bisphosphate to generate PI 3, 4, 5 triphosphate. 
Structurally, Class I PI-3K enzymes are heterodimeric proteins comprising of a 
regulatory subunit (p85) and a catalytic subunit (p110) (250). PI-3K is activated upon 
binding of Src homology-2 (SH2) domain of the regulatory subunit (p85) binds the 
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Figure 4.2 Effects of MAPK Inhibitor PD98059 on Cell Motility 
 
Mean cell migration of Mock and A6 cells (n=2) treated with DMSO, 50 and 100 µM 
concentration of MAPK inhibitor, PD98059. The error bars represent the standard 
deviation. 
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phosphotyrosine residues (251) generated upon activation of growth factors or integrins.  
The p85 subunit of PI-3K then recruits the catalytic (p110) subunit into the 
proximity of membrane associated phosphoinositides. The p110 catalyses the 
phosphorylation of 3rd hydroxyl group of the inositol ring leading to generation of 
phosphatidylinositol-3 phosphates. It has widely been accepted that PI-3K pathway is 
important for cell migration. For example, in CHO cells, haptotactic motility to FN was 
shown to be predominately regulated by the PI-3K pathway (252). Based on these 
observations, we examined the contribution of PI-3K to CD9 mediated haptotactic cell 
migration.  
In independent experiments, two inhibitors of PI-3K pathway were used in the 
haptotactic motility assays. Wortmannin, is a fungal metabolite that acts by 
irreversiblyinhibiting the catalytic subunit of the PI-3K (253). Wortmannin, while at nM 
concentrations specifically inhibits PI-3K, µM concentrations were shown to inhibit other 
important signaling molecules such as the myosin light chain kinase and phospholipase D 
that are involved in cell migration (254, 255). Therefore the effects of wortmannin on 
Mock, A6 cell migration were tested at three different concentrations. 
Figure 4.3 depicts the results of the Mock, A6 cell migration in the presence of 
wortmannin. Inhibition of A6 cell migration was observed at wortmannin concentrations 
as low as 0.2 µM (p=0.007 as compared to DMSO control) while higher concentrations 
of wortmannin (10 µM) inhibited the migration of both Mock and A6 cells. Thus 
wortmannin had a dose dependent inhibition of A6 cell migration while vehicle control 
DMSO did not affect the motility of Mock or A6 cells.  
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Figure 4.3 Effects of PI-3K Inhibitor Wortmannin on Cell Motility 
 
Mean cell migration of Mock and A6 cells (n=3) treated with DMSO and 0.2, 1, 10 µM 
wortmannin. * Indicates p value < 0.05 as compared to the respective DMSO (0) treated 
control group.The error bars represent the standard deviation. 
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LY294002 is a specific inhibitor of PI-3K that competes with ATP at the catalytic 
site of the enzyme (256). LY294002 has been shown to be a more selective inhibitor of 
PI-3K than wortmannin. Therefore, to validate the results obtained with wortmannin, 
motility assays were performed with LY294002. Figure 4.4 shows the results of the 
motility assays performed in the presence of two different concentration of LY294002. 
The results indicate that inhibition of PI-3K by LY294002 had a dose response inhibition 
on CD9 promoted haptotactic cell migration. A statistically significant difference in A6 
cell migration was observed with LY294002 concentration of 25 and 50 µM (p < 0.001) 
as compared to DMSO control). Carrier compound DMSO did not significantly affect the 
motility of Mock or A6 cells. 
In summary, motility assays performed with pharmacological inhibitors to crucial 
signaling molecules clearly indicated that CD9 promoted haptotactic cell migration in 
CHO cells does not require either PKC or MAPK. The finding that CD9 promoted 
migration is blocked by two structurally different inhibitors of the PI-3K pathway suggest 
that PI-3K may be an essential pathway required for CD9 mediated cell migration.  
 
4.2 PI-3K in CD9 Mediated Cell Motility 
In order to confirm the results obtained with the pharmacological inhibitors of PI-
3K, we aimed to suppress the endogenous PI-3K activity by molecular methodology. 
Dominant/negative forms of the protein are widely being used to suppress the activity of 
several signaling molecules (257).  Since dominant/negative forms exclusively down 
regulate the function of targeted protein of interest, they are in a way more specific than 
pharmacological inhibitors to inhibit a specific signaling pathway. 
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Figure 4.4 Effects of PI-3K Inhibitor LY294002 on Cell Motility
 
Mean cell migration of Mock and A6 cells (n=3) treated with DMSO and 25 and 50 µM 
LY294002. * Indicates p value < 0.05 as compared to the DMSO treated A6 cells. The 
error bars represent the standard deviation. 
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Suppression of PI-3K activity in cells can be achieved by overexpression of 
dominant/negative form of the PI-3K. The PI-3K dominant/negative construct used in our 
study expresses a mutant form of the regulatory subunit designated as ∆p85. The ∆p85 
form of PI-3K lacks the crucial domain that is necessary for interaction with the p110 
subunit. Since, p110 subunit interaction with the regulatory (p85) subunit is a prerequisite 
for PI-3K activation, over expression of ∆p85 leads to suppression of endogenous PI-3K 
activity (217).  
Mock and A6 cells were transiently transfected either with a GFP expression 
plasmid (pEGFP-N1) or a plasmid that expresses a ∆p85 as described in Materials and 
Methods. The conditions for the expression of the ∆p85 subunit were optimized using the 
lipofectamine protocol. In all the experiments, expression of ∆p85 subunit was confirmed 
by Western blot analysis of whole cell lysates made 72 hrs post transfection. A 
polyclonal antibody against p85 subunit was employed in the western blots.  
As shown in Figure 4.5, both Mock and A6 cells expressed comparable levels of 
endogenous p85 subunit and transient expression of ∆p85 plasmid but not the GFP 
plasmid led to expression of ∆p85 subunit. As expected, the endogenous p85 was 
recognized as a separate band that ran at slightly higher molecular weight than the 
overexpressed ∆p85 (Figure 4.5). 
Since PI-3K pathway is important in cell survival and proliferation pathways, 
over expression of dominant/negative form of PI-3K has been shown to induce apoptotic 
cell death (258). Since we intended to use the dominant/negative PI-3 kinase transfected 
CHO cells in migration assays; viability of cells was first assessed by trypan blue dye 
exclusion before subjecting the cells to haptotactic motility. Consistent with an earlier 
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Figure 4.5 Western Blot Analysis after Dominant/Negative PI-3K Transfection
 
Expression of ∆p85 and GFP in Mock and A6 cells after transient transfection with ∆p85 
and GFP expression plasmids. Endogenous PI-3K (p85) and the ∆p85 (top panel) were 
detected with a polyclonal anti-PI-3K antibody and GFP (bottom panel) was detected 
with an anti-GFP mAb. 
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finding (259), expression of dominant/negative PI-3K plasmid in CHO cells did not 
affect the cell viability.   
To test the effects of dominant/negative PI-3K in CD9 mediated haptotactic cell 
motility, Mock and A6 cells transiently transfected with pEGFP-N1 or the ∆p85 plasmid 
were subjected to transwell migration assays on FN. As shown in Figure 4.6, 
dominant/negative transfections with the ∆p85 construct significantly inhibited migration 
of A6 cells (p=0.039) when compared to the Mock cells. The expression of GFP plasmid 
alone did not alter the migration potential of these cells (Figure 4.6). These results 
clearly show that PI-3K pathway is crucial for CD9 mediated cell migration on FN. 
Subsequent to PI-3K activation, phosphoinositides are specifically recognized by 
the pleckstrin homology (PH) domain containing proteins. Akt, also known as protein 
kinase B (PKB), is a PH domain containing serine/ threonine protein kinase that is 
phosphorylated and activated downstream of PI-3K (260).  Akt is specifically 
phosphorylated on a serine 473 residue in a PI-3K dependent manner (261, 262). 
Phosphorylation of Akt on serine 473 has been shown to correlate with the kinase activity 
(261). Thus Akt phosphorylation on serine 473 residue serves as an indicator of PI-3K 
activity. 
As our results using pharmacological inhibitors and the dominant/negative PI-3K 
showed the involvement of PI-3K in CD9 mediated cell motility, we next compared the 
phosphorylation state of Akt in Mock and A6 cells in response to adhesion to FN. For 
these experiments, cultured Mock and A6 cells were harvested and whole cell lysates 
were prepared from cells either held in suspension or that were plated onto FN for 1 hr. 
Subsequently, Akt phosphorylation was examined using a specific antibody that  
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Figure 4.6 Effects of PI-3K Dominant/Negative (∆p85) Transfection on Cell Motility
 
Mean cell migration of Mock and A6 cells (n=3) treated with control GFP plasmid and 
∆p85 plasmid. * represents p < 0.05 as compared to the GFP transfected A6 cells. The 
error bars represent the standard deviation. 
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specifically binds phosphorylated S473 in Western blots.  
Cell adhesion to FN can activate PI-3K in integrin α5β1 dependent manner. 
Therefore, as expected in response to cell adhesion to FN, Akt phosphorylation was 
increased both in Mock and A6 cells when cells were plated on to FN as compared to the 
suspension cells (Figure 4.7). Consistent with our earlier observations that CD9 can 
stimulate PI-3K pathway, CD9 expressing cells had significantly higher levels of 
phosphorylated Akt when cells were plated onto FN compared to Mock controls (Figure 
4.7). 
No significant differences in Akt phosphorylation were observed between Mock 
and A6 cells when cells were held in suspension. As the differences in phosphorylation 
states can be attributable to the total amount of protein present in the samples total 
cellular levels of actin were also compared between Mock and A6 cells. As shown in 
bottom panel of Figure 4.7, total levels of cellular actin did not significantly differ for 
Mock and A6 cells. To quantify the data, scanned Western blots were subjected to 
densitometry scanning and phosphorylation of Akt was expressed in relation to actin. As 
shown in Figure 4.8, one hr after plating the cells on to FN, A6 cells have a three fold 
increase in relative Akt phosphorylation as compared to Mock cells. 
 
4.3 Adenoviral Vectors for Transient Expression of CD9 
Adenovirus mediated transient expression of transgenes has significant advantage 
over generation of stable cell lines expressing the gene of interest for the following 
reasons. Firstly, adenoviral system can be used to express proteins in cells that have 
limited in vitro growth capabilities (primary cells) and where generating stable cell line is  
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Figure 4.7 Effects of Stable Expression of CD9 on Akt Phosphorylation 
Mock and A6 cells held in suspension (sus) or plated on to FN for 1 hr were analyzed for 
the phosphorylation of Akt on Serine 473 with a phospho-specific antibody (top panel). 
The same lysates were analyzed for total cellular actin (bottom panel). 
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Figure 4.8 Quantification of Akt Phosphorylation in Mock and A6 Cells 
 
Ratios of phosphorylated Akt and actin were compared between Mock and A6 cells 
either held in suspension (0 hr) or plated onto FN (1 hr) (n=3). The error bars represent 
the standard deviation. 
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not possible. Secondly, the levels of expression of the protein of interest can be controlled 
by using different virus multiplicity of infection (MOI). Thirdly, adenovirus does not 
integrate into the host genome thus avoiding the problems associated with the random 
insertions of transgenes into the native gene sequences. Finally, adenoviral vectors can be 
used for in vivo gene transfer in to animal tissues. For these reasons, adenovirus capable 
of expressing full-length human CD9 was generated as described in the Materials and 
Methods section. 
At first, we tested the ability of adenovirus to express full-length CD9 (Ad-CD9) 
in cultured cells. Expression of CD9 was evaluated 72 hrs after the adenoviral 
transduction. Figure 4.9 depicts the Western blot results of CD9 expression in primary 
rat aortic smooth muscle (RASM) cells transduced with three different concentrations of 
the Ad-CD9 virus.  As expected, the levels of CD9 expression correlated with viral dose 
and maximal expression of CD9 was seen at 100 MOI.  Despite the extent of CD9 
expression, adenoviral transductions did not affect the viability of cells as determined by 
trypan blue exclusion. Therefore, an MOI of 100 was chosen for subsequent experiments.  
In order to corroborate the Western blot results and to confirm successful 
expression of human CD9 as a surface protein in RASM cells, FCM was used. FCM 
experiments with untreated and Ad-CD9 treated RASM cells showed that the anti-human 
CD9 mAb (mAb7) caused a significant right shift in the mean fluorescence intensity only 
in the Ad-CD9 treated cells (Figure 4.10). The isotype control antibody (MIgG, MOPC-
21) only showed background fluorescence in both untreated and Ad-CD9 treated cells 
(Figure 4.10). These results clearly showed that after Ad-CD9 treatment, human CD9 
was successfully expressed on the cell surface of RASM cells. Similar results were  
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Figure 4.9 Western Blot Analysis for CD9 Expression after Adenoviral Transduction 
 
Untreated, Ad-LacZ treated, and Ad-CD9 treated (25, 50,100 MOI) vascular smooth 
muscle cells were analyzed for CD9 expression using anti-human CD9 (mAb7). MOI: 
multiplicity of infection. 
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Figure 4.10 FCM Analysis of CD9 Expression in RASM Cells 
 
Untreated and Ad-CD9 treated RASM cells were labeled with mouse IgG (MIgG) or 
CD9 specific mAb (mAb7). 
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observed with two other cell lines, CHO, and the mouse breast cancer cell line [Jyg 
MC(A)] transduced with the CD9 adenoviral construct (data not shown).  
Adenoviral infection of cells or adenoviral mediated gene expression can have 
adverse effects on cell surface integrin expression. Additionally, expression of 
tetraspanins has also been reported to downregulate integrin expression. For example, He 
et al reported that in DU145 prostate cancer cell line, CD82 expression downregulates 
integrin α6 function by accelerating its internalization (15). CD82 and a few other 
tetraspanins (CD151, CD63, and CD37) possess a tyrosine-based endosomal/lysosomal-
targeting motif in their C-terminal cytoplasmic region is thought to be responsible for 
internalization of integrins (15).  
Therefore, our next objective was to investigate whether adenoviral mediated 
CD9 expression influenced cell surface integrin expression in RASM cells. To address 
this issue, we performed FCM experiments to compare the expression pattern of various 
integrins in adenoviral transduced RASM cells. Table 4.2 shows the mean fluorescence 
intensity (MFI) values obtained for integrin levels in untreated RASM cells or RASM 
cells infected with Ad-CD9 virus. As shown in Table 4.2 no significant differences in the 
MFI were detected for constitutive integrins α1, α5, and β1. Cultured RASM cells did 
not express significant levels of integrin β3 (Table 4.2, Figure 4.11).  
Similar results were obtained with Ad-LacZ transduced RASM cells.  The top 
panel of Figure 4.11 also depicts the histograms for the expression of α5 and β1 integrin 
subunits in RASM cells before and after Ad-CD9 transduction. These results show that 
expression vector Ad-CD9 is capable of expressing a recombinant CD9 in RASM cells, 
and that viral transduction or CD9 expression did not alter key cell surface integrin 
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Table 4.2 Comparison of CD9 and Integrin Expression in RASM Cells 
 
Antibody Untransduced Ad-CD9 Transduced 
(100 MOI) 
mIgG* 8.7 ± 5.9 6.9 ± 2.1 
hIgG** 6.9 ± 2.0 6.6 ± 0.2 
Human CD9 (mAb7) 6.3 ± 0.6 822 ± 309 
α1 (3A3) 235.6 ± 32.4 234.2 ± 24.1 
α5 (HM α5-1) 18.5 ± 4.7 17.4 ± 3.3 
β1 (HM β1-1) 81.7 ± 6.4 78.7 ± 7.6 
β3 (F11) 10.7 ± 2.6 10.3 ± 2.4 
 
Note: The numbers represent the mean fluorescence intensities ± standard deviation from 
3 independent experiments. * Mouse IgG ** Hamster IgG. 
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Figure 4.11 FCM Analysis of Integrin Expression in RASM Cells 
 
Untreated and Ad-CD9 treated RASM cells were analyzed for the surface expression of 
Integrins. The histograms depict the expression of Integrins α5, β1 (top panel), α1 and 
β3 (bottom panel). MIgG: mouse IgG. 
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expression. CD9 lacks the unique c-terminal tyrosine based internalization motif present 
in other tetraspanins (CD82, CD63, and CD151) and thus does not influence steady state 
levels of cell surface integrins. 
 
4.4 Effects of Transient Expression of CD9 on Akt Phosphorylation 
Since our data from CD9 stable transfection in CHO cells shows that PI-3K is 
activated upon CD9 expression, we intended to study the affects of transient expression 
of CD9 on Akt phosphorylation. For these experiments, we utilized RASM cells treated 
with Ad-LacZ, Ad-CD9 viruses and untreated RASM cells. As seen in CHO cells, 
adhesion of RASM cells to FN caused significant increases in Akt phosphorylation on 
S473 residue as compared to the cells held in suspension (Figure 4.12).   
CD9 expression in RASM cells significantly increased Akt phosphorylation in FN 
dependent manner. Total levels of Akt did not significantly differ between these cell 
types indicating that adenoviral transduction did not affect total Akt levels. The enhanced 
phosphorylation of Akt on S473 site in CD9 expressing cells was abolished when cells 
were pretreated with PI-3K inhibitor, LY294002 (Figure 4.12).  Quantification by 
densitometry showed that phosphorylated Akt was approximately two fold higher in CD9 
expressing cells as compared with the control cells (Figure 4.13). These results suggest 
that PI-3K activation in CD9 expressing CHO cells was not due to an aberrant stable 
clone and that the effect is a specific CD9 linked phenomenon.  
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Figure 4.12 Effects of Transient Expression of CD9 on Akt Phosphorylation 
 
Untransduced, Ad-CD9, Ad-LacZ transduced (MOI-100) RASM cells were either held in 
suspension or plated onto FN coated culture dishes for 3 hrs. Whole cell lysates were 
analyzed for phosphorylation of Akt on Serine 473 (top panel) and the same blot was 
stripped and reprobed for total Akt (bottom panel). The last lane represents lysates from 
Ad-CD9 transduced cells showing inhibition of Akt phosphorylation on Serine 473 with 
the PI-3K inhibitor LY294002. 
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Figure 4.13 Quantification of Akt Phosphorylation in RASM Cells 
 
Ratios of phosphorylated Akt and total Akt compared between untreated, Ad-LacZ 
treated and Ad-CD9 treated vascular smooth muscle cells plated onto FN for 3 hrs (n=3). 
The error bars represent the standard deviation. 
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4.5 The Role of p130Cas in CD9 Mediated Cell Motility 
It is well documented that cell adhesion to extracellular components leads to 
enhanced tyrosine phosphorylation of key signaling molecules. Tyrosine phosphorylation  
of high molecular weight proteins (above 100 kDa) has also been shown to activate PI-
3K pathway. In order to determine the potential effects of CD9 expression on protein 
tyrosine phosphorylation, we compared the adhesion associated tyrosine phosphorylation 
in Mock and A6 cells.  
Lysates prepared from cells held in suspension or that were plated onto FN for 2 
hr and 3 hr were analyzed by Western blot with anti-phosphotyrosine mAb. Adhesion of 
both Mock and A6 cells to FN led to significant increase in tyrosine phosphorylation of a 
protein in the molecular weight range of 105-250. Additionally, A6 cells plated onto FN 
have siginificantly higher rates of tyrosine phosphorylation of this band as compared to 
the Mock cells. Since, both  p130Cas (130 kDa) and FAK (120 kDa) are candidate 
molecules within this molecular weight range (263), we subsequently focused on 
studying these molecules (Figure 4.14). 
p130Cas is an adapter protein that has been reported to be activated upon cell 
adhesion to ECM (263, 264). Tetraspanins have been reported to mediate signaling via 
the p130Cas pathway. For example, expression of CD82, a metastasis suppressor 
tetraspanin, in prostate cancer cells led to down regulation of p130Cas total protein levels 
with concomitant inhibition of cell motility (39). Because of these observations, we 
investigated the possible involvement of p130Cas in CD9 mediated cell migration. 
Firstly, to determine whether CD9 expression affected p130Cas expression, 
Western blot was performed on whole cell lysates prepared from Mock and A6 cells.  
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Figure 4.14 Analysis of Protein Tyrosine Phosphorylation in Mock and A6 Cells 
 
Western blot analysis of cell lysates with anti-phosphotyrosine mAb showed that A6 cells 
have enhanced tyrosine phosphorylation of proteins in the molecular weight range 105-
250 kDa. 
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Figure 4.15 shows that levels of p130Cas were significantly higher in CD9 
expressing cells as compared to the Mock cells. The total levels of Focal Adhesion 
Kinase (FAK) and actin did not differ between these two cell types (Figure 4.15). 
Densitometry quantification of p130Cas and actin indicated that p130Cas levels in A6 
cells were approximately 58% higher in CD9 expressing cells as compared to the Mock 
cells (Figure 4.16). 
FAK was shown to be tyrosine phosphorylated upon integrin activation (194, 
265). Specifically, phosphorylation of FAK on tyrosine (Y) 397 has been shown to be 
responsible for its activation (194, 266) Therefore, we compared the adhesion dependent 
phosphorylation of FAK on Y397 residue in Mock and A6 cells. Although cell adhesion 
to FN enhanced phosphorylation of FAK on Y397, no significant differences were 
observed between Mock and A6 cells (data not shown). 
Tyrosine phosphorylation of p130Cas creates docking sites for the SH domain 
containing proteins, that leads to activation of downstream signaling pathways. To 
understand whether the increase in p130Cas protein levels contributed to changes in its 
tyrosine phosphorylation state, the following experiments were performed. Mock and A6 
cells were either held in suspension or were allowed to adhere to FN for the indicated 
time and cell lysates were prepared as described in the material and methods.  
Subsequently, p130Cas was immunoprecipitated from cell lysates using specific 
mAb and the resulting immunoprecipitates were separated on SDS-PAGE. Tyrosine 
phosphorylation state of immunoprecipitated p130Cas was detected using anti-
phosphotyrosine antibody (RC-20HRP). No significant differences in tyrosine 
phosphorylation of p130Cas were observed between Mock and A6 cells held in  
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Figure 4.15 Western Blot Analysis of p130Cas Expression in Mock and A6 Cells 
 
Whole cell lysates from Mock and A6 cells were analyzed for the expression of p130 Cas 
(top panel) FAK (middle panel) and total cellular actin (bottom panel). 
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Figure 4.16 Quantitative Comparison p130Cas Expression in Mock and A6 Cells 
 
Results of the scanning densitometry showing ratio between total p130Cas and total 
FAK. The error bars represent the standard deviation. 
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suspension. However, in both Mock and A6 cells, p130Cas was increasingly tyrosine 
phosphorylated at 1 hr and 2 hr after cell adhesion to FN (Figure 4.17). In cells plated 
onto FN, corresponding to the increased levels of p130Cas in A6 cells, the extent of 
tyrosine phosphorylation of p130Cas was also significantly higher than in the Mock cells. 
These results clearly suggested that CD9 expression can up regulate p130Cas protein 
levels and tyrosine phosphorylation state. 
p130Cas has been reported to play an important role in directional migration of 
cells to FN (267). Interestingly, CD82 mediated suppression of metastasis has been 
shown to be due to downregulation of p130Cas levels in DU-145 cells (39). As CD9 
expression promotes directional migration of CHO cells to FN and also alters the total 
levels and phosphorylation of p130Cas, we next examined if p130Cas contributed to CD9 
mediated haptotactic cell motility. To address the role of p130Cas in CD9 mediated 
motility, we utilized siRNA gene silencing methods to suppress the endogenous levels of 
p130Cas. 
Since A6 cells have an up regulated p130Cas protein levels as compared to the 
Mock cell, the goal of p130Cas siRNA transfection experiments was to specifically 
suppress endogenous p130Cas levels in A6 cells to that seen in Mock cells and then to 
study its affects on cell migration. As a hamster specific sequence for the p130Cas was 
not available for designing siRNA duplexes, we utilized the mouse siRNA duplexes that 
were first tested for their potential to inhibit p130Cas message in the CHO cells. 
Transient transfection experiments with control or the p130Cas siRNA duplexes 
were performed as described in Materials and Methods section. Transient transfection of 
Mock and A6 cells with p130Cas siRNA duplexes resulted in significant down regulation 
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Figure 4.17 Western Blot Analysis of p130Cas Tyrosine Phosphorylation 
 
p130Cas was immunoprecipitated from Mock, A6 cell lysates and Western blot was 
performed for tyrosine phosphorylation (pTyr) (top panel). The blots were subsequently 
stripped and re probed for total p130Cas (Bottom panel). 
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of endogenous p130Cas protein levels. As expected, transfection of cells with the control 
siRNA did not alter the endogenous levels of p130Cas (Figure 4.18). In order to 
demonstrate the specificity of siRNA duplexes, total cellular levels of actin were also 
examined. As shown in bottom panel of Figure 4.18, neither p130Cas nor the control 
siRNA transfections altered the total cellular levels of actin. These results demonstrated 
that hamster p130Cas has significant sequence homology to the mouse p130Cas and that 
mouse p130Cas siRNA duplexes can be successfully used to knock down p130Cas in 
CHO cells.  
After validating the utility of mouse p130Cas siRNA duplexes in CHO cell model 
system, we further proceeded to investigate the effects of knockdown of p130Cas in CD9 
mediated cell motility. To investigate this we performed haptotactic motility assays on 
FN. Twenty-four hrs after transfection with siRNA duplexes, Mock and A6 cells were 
harvested and subjected to transwell migration assays as described earlier. As expected, 
control siRNA transfection did not significantly affect the migration of Mock and A6 cell 
on FN and A6 cells still maintained a three fold higher migration than the Mock cells. No 
significant differences in cell migration were noted between A6 cells transfected with 
control or p130Cas siRNA (Figure 4.19).  
Although overall p130Cas levels in lysates from A6 cells after p130Cas-siRNA 
transfection were reduced to those in the Mock cells (Figure 4.18) transfected with 
control siRNA, A6 cells had 3-4 fold higher migration than Mock cells. Since the 
percentage of transfection efficiency using p130Cas siRNA duplex has not been 
estimated and because a majority of motile cells may not actually represent the p130Cas 
siRNA transfected cells, the above results should be interpreted with caution. Alternative  
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Figure 4.18 Western Blot Analysis after p130Cas siRNA Transfection 
 
Levels of p130Cas (top panel) and actin (bottom panel) after transfection of Mock and 
A6 cells with either control siRNA duplex or the p130Cas SiRNA duplex. 
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Figure 4.19 Motility of Mock and A6 cells after p130Cas siRNA Transfection 
 
Mean cell migration of Mock and A6 cells after transient transfection with control siRNA 
duplex (Ctr) or the p130Cas siRNA duplex (p130Cas) (n=3). The error bars represent the 
standard deviation. 
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methods with high efficiency transfection rates such as the lentivirus vector mediated 
downregulation of p130Cas may conclusively prove the role of p130Cas in CD9 
mediated phenotypes. Thus the functional implication of upregulated p130Cas in CD9 
expressing cells remains to be elucidated.  
 
4.6 Physical Association of CD9 with Integrins 
Members of the TM4SF family proteins can associate with each other and with 
integrins to form multimeric complexes on the cell membrane often referred to as the 
“tetraspanin web” (9). The characteristic feature of the tetraspanin-integrin interactions is 
their sensitivity to disruption by stronger detergent solutions such as Triton-X 100. 
Therefore, most tetraspanin-integrin associations are evident only in cell lysates prepared 
with mild detergent solutions such as Brij-98, Brij-99 and CHAPS. Few tetraspanins such 
as CD151 and CD81 retain the capability to interact with integrins even under stringent 
detergent conditions (3, 268). Thus within the tetraspanin web, CD151 and CD81 are 
thought to maintain primary or direct interactions with the integrins which are 
characterized by their specificity and stoichiometry.  
It has been further hypothesized that other TM4SF members such as CD9 
participate in primary complexes via secondary or indirect interactions (3). Secondary 
interactions, in contrast to primary interactions are sensitive to disruption by stronger 
detergents like Triton-X100. Although CD9 has been shown to associate with integrins 
containing β1 and β3 subunits, so far, there is no evidence showing CD9 is able to 
maintain direct interactions with these integrins. While CD9-β1 associations have been 
demonstrated in virtually all the cell types tested (138), CD9-β3 association seem to be 
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restricted to platelets and hematopoietic cell lines (108). In a given tissue, the overall 
composition of tetraspanin web is determined by the expression pattern of both integrins 
and tetraspanins.  
In the current study our initial goal was to optimize the conditions for IP using the 
mild detergent Brij-98. Using Brij-98 lysis buffer to solubilize the membrane proteins we 
studied the interaction of CD9 with integrins. Human platelets express both CD9 and β3 
integrin (GPIIb/IIIa) and hence were used to study CD9-β3 interactions. Isolation, protein 
preparation and IP from platelet lysates were carried out as described in the material and 
methods. Figure 4.20 depicts the results of Western blot analysis for the detection of 
platelet integrins GPIIb and IIIa (β3) in mAb7 immunoprecipitates. Bands corresponding 
to both integrin subunits were detected in mAb7 immunoprecipitates. The mouse IgG 
negative control (MOPC-21) antibody did not immunoprecipitate either of these proteins.  
IP of GPIIb from platelets with the 10E5 mAb resulted in co-IP of CD9. 
Similarly, IP of IIIa (β3) with AP3 mAb also resulted in co-IP of CD9. These results 
were consistent with several earlier observations demonstrating CD9-GPIIb/IIIa 
association and thus validated the use of Brij-98 lysis buffer to identify CD9-integrin 
interactions (108, 110). Since GPIIb/IIIa is the major integrin on platelets that express 
only moderate levels β1 containing integrins, it would be interesting to identify the 
components of tetraspanin web in human platelets. In addition to CD9, platelets also 
express tetraspanin CD151. We anticipate that our experimental methods are valuable 
tools in understanding the complex nature tetraspanin-integrin interactions in human 
platelets.  
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Figure 4.20 Association of CD9-GPIIb/IIIa in Platelets 
 
Brij-98 lysates from the platelets were immunoprecipitated (IP) with antibodies specific 
for CD9, GPIIb/IIIa complex, and GPIIIa or the mouse IgG control (MIgG). 
Immunecomplexes were subsequently analyzed by Western blot for CD9 (top panel), 
GPIIb (middle panel) and GPIIIa (bottom panel). 
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The association between CD9 and β1 was studied using cultured cells. In HT1080 
cells, only small amounts of endogenous CD9 were expressed as detected by FCM. 
Therefore, we generated stable CD9 expressing cell line (CD9-HT1080) as described in 
materials and methods. Lysates from Mock transfected HT1080 cells and CD9-HT1080 
cells were prepared and IP experiments were performed as described in materials and 
methods. Figure 4.21 shows the results of these experiments where presence of β1 
integrin was detected by Western blot analysis of immunoprecipitated proteins. 
As expected the mouse IgG control mAb did not immunoprecipitate integrin β1 
from cell lysates. A band corresponding to β1 integrin was detected from both Mock and 
CD9 HT1080 lysates, where anti-human β1 mAb, TS2/16, was used for IP. IP of CD9-
HT1080 cell lysates with mAb7 resulted in β1 co-IP. As Mock HT-1080 cells expressed 
only insignificant levels of CD9, a band corresponding to β1 integrin was not detected in 
mAb7 immunoprecipitates from these cells. These results further validated the usability 
of Brij-98 detergent to demonstrate CD9-integrin interactions.  
After demonstrating CD9-β1 interaction in HT1080 cells, we furthered our study 
to demonstrate CD9 interactions with integrin α5β1. So far CD9-α5β1 interactions have 
been demonstrated in very few cell types such as trophoblasts and myocytes (99, 135). To 
determine whether α5β1, associates with CD9, we carried out experiments using RASM 
cells transduced with the Ad-CD9 vector. The relationship between α5β1 and CD9 was 
examined by IP experiments where untransduced RASM cells served as negative 
controls.  
As shown in Figure 4.22, CD9 was immunoprecipitated with anti-human CD9 
mAb (mAb7) only from cells expressing recombinant human CD9 but not from the 
 109
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
β1 blot
CD9 blot
β1
 IP
C
D
9  
I P
L
ys
at
e
m
Ig
G
IP
L
ys
at
e
C
D
9 
IP
β1
 IP
m
Ig
G
IP
Mock-HT1080 CD9-HT1080
 
 
 
Figure 4.21 Association of CD9 and Integrin β1 in HT1080 Cells 
 
Brij-98 lysates from Mock-HT1080 and CD9-HT1080 cells were immunuprecipitated 
with mouse IgG (mIgG), CD9 and integrin β1 mAbs as described in Materials and 
Methods. Immunecomplexes were analyzed for integrin β1 (top panel) and CD9 (bottom 
panel). 
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Figure 4.22 Association of CD9 with Integrin β1 in RASM Cells 
 
Brij-98 lysates from untransduced (control) and Ad-CD9 transduced (Ad-CD9) were 
immunoprecipitated with mouse IgG (mIgG) anti-human CD9 (mAb7), anti-rat CD9 
mAb (α-rat CD9) and immunoprecipitates were analyzed for integrin β1 (top panel) and 
CD9 (bottom panel). 
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control cells. MOPC-21 (mIgG control) did not immunoprecipitate CD9 either from 
control cells or from CD9 expressing RASM cells. No significant differences in α5 and 
β1 integrin subunit protein levels were detected between the control cells and Ad-CD9 
transduced cells. Western blot analyses of mAb7 immunoprecipitates indicated that both 
the integrin subunits α5 and β1 co-immunoprecipitated with CD9 (Figure 4.22, Figure 
4.23).  
Two bands corresponding to mature and immature chains of integrin β1 were 
detected by Western blot under reducing conditions (Figure 4.22). Sequential IP and 
Western blotting with two different mAbs (HMβ1-1, BD clone-18) to β1 confirmed that 
these two bands indeed corresponded to the β1 integrin subunit. The higher molecular 
weight band corresponded to the mature (fully glycosylated) form of integrin β1 and the 
lower molecular weight band the immature (partially glycosylated) form (269, 270).  
Only the mature integrin β1 was detected in CD9 immunoprecipitates. As expected, 
neither CD9, α5, nor β1 subunits co-immunoprecipitated with CD9 from the control 
cells. 
These results confirmed our hypothesis that CD9 is in association with integrin 
α5β1. Additionally, the observation that CD9 only immunoprecipitated higher molecular 
weight forms of β1 suggested that maturation of β1 by post translational modification 
such as glycosylation is an essential requirement for CD9-β1 interactions. An α5β1-CD9 
association was not detected in higher stringency Triton X-100 derived cell lysates (data 
not shown). Susceptibility of CD9-α5β1 complexes for disruption by stronger detergents 
is consistent with earlier finding and whether CD9 requires other tetraspanins such as 
CD151 to maintain α5β1 interaction remains to be investigated. 
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Figure 4.23 Association of CD9 with Integrin α5 in RASM Cells 
 
Brij-98 lysates from untransduced (control) and Ad-CD9 transduced (Ad-CD9) were 
immunoprecipitated with mouse IgG (mIgG), hamster IgG (HIgG), anti-human CD9 
(mAb7), anti-rat α5 mAb (HMα5-1) and anti-rat β1 mAb (HMβ1-1) and 
immunoprecipitates were analyzed for integrin α5. 
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Although ectopic expression of proteins in cultured cells is an invaluable tool in 
understanding the characteristics of a protein, exogenous expression systems are prone to 
false positive findings. For example, non-specific protein-protein interactions can occur 
when proteins are expressed above the physiological levels directly contributing to the 
false positive results. To circumvent these problems, we tested CD9-α5β1 interactions 
using a cell line where both CD9 and α5β1 are expressed endogenously. Testing of 
several cell lines available to us showed that mouse embryonic fibroblasts (MEF) 
expressed significant levels of both CD9 and α5β1 and therefore were used for 
subsequent testing.  
Figure 4.24 shows the results of FCM experiments performed on MEF for the 
detection of CD9, α5, and β1. As shown in the left panel of Figure 4.24, mAbs specific 
for integrin subunits α5, β1 caused a right shift in the fluorescence intensity as compared 
to the hamster IgG isotype (control) antibody. The right panel of Figure 4-24 depicts 
similar right shift in fluorescence intensity observed with the rat monoclonal antibody 
against mouse CD9 (KMC.8). These results confirmed the expression of integrin α5, β1 
and CD9 in MEF. 
In order to demonstrate the physical association between CD9 and α5β1 in MEF, 
α5, β1 and CD9 were immunoprecipitated from cell lysates prepared with Brij-98 lysis 
buffer. The presence of α5 in the immunoprecipitates was detected using a polyclonal 
antibody against α5. As shown in Figure 4.25, a band corresponding to α5 was detected 
in both α5, β1 mAb immunoprecipitates. As expected, the hamster IgG isotype matched 
antibody did not immunoprecipitate α5. Supporting our findings from RASM cell model 
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Figure 4.24 FCM Analysis of CD9 and α5β1 Expression in MEF 
 
Flow cytometry (FCM) analysis of mouse embryonic fibroblast (MEF) cells for the 
expression of integrins α5, β1 (left panel) and CD9 (right panel). 
 
 
 
 
 
 
 
 
 
 
 
 115
 
 
 
 
 
 
 
 
 
 
 
 
 
R
at
 Ig
G
IP
C
D
9 
IP
H
 Ig
G
IP
α5
 IP
 
β1
 IP
α5 blot
 
 
 
Figure 4.25 Association of CD9 with Integrin α5 in MEF 
 
Brij-98 lysates from mouse embryonic fibroblasts (MEF) were immunoprecipitated with 
Rat IgG, anti-CD9, hamster IgG (HIgG), anti-α5 and anti-β1 antibodies and 
immunoprecipitates were analyzed by Western blot for α5 integrin. 
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systems, a band corresponding to α5 integrin was also detected in anti-CD9 mAb 
(KMC.8) immunoprecipitates (Figure 4.25). 
Previous work from our laboratory using confocal laser scanning microscopy 
(CLSM) experiments showed that CD9 co-localizes with β1 integrin in CHO cells (200). 
Co-localization experiments with CLSM, although prove the spatial proximity of proteins 
do not confirm the physical association between proteins. Also the regions of CD9 
required for interaction with α5β1 appear to be highly conserved as recombinant human 
CD9 was able to associate with rat α5β1 integrin. 
Our findings underscore an important regulatory role of CD9 in vascular smooth 
muscle cell (VSMC) functions. We show that in VSMC CD9 associates with integrin 
α5β1 and can activate α5β1 dependent signaling pathways. CD9 expression has been 
shown to correlate with the proliferative phenotype of VSMC (93). Proliferative 
phenotype of VSMC is predominantly seen in the injured vessel where there is also 
extensive α5β1 dependent ECM reorganization (271). Based on our observations, we 
hypothesize that in VSMC, increases in CD9 expression have potential functional 
implications regulating vascular injury response. 
 
4.7 The Role of Integrins in CD9 Mediated Cell Motility
Although it is well known that CD9 and other tetraspanins associate with a variety 
of integrins, it is in unknown whether tetraspanins can directly regulate integrinfunctions. 
Tetraspanin CD151 has been recently shown to stabilize the active conformation of 
integrin α3β1 and upregulate its ligand binding activity (206). Several of CD9 induced 
phenotypic changes in cells are specific for FN that is known to be a classical receptor for 
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α5β1. Our finding that CD9 is in complex with integrin α5β1 further prompted us 
investigate the contribution of this integrin in CD9 mediated phenotypic changes.  
In addition to integrins, CD9 has also been shown to interact with growth factor 
related receptors. Expression of CD9 has been shown to up regulate the activity of 
membrane bound heparin binding epidermal growth factor-like growth factor (Pro-HB-
EGF) (33). To investigate whether CD9 promoted motility may be due to modulation of 
growth factor receptors responding to their soluble ligands, the following experiments 
were performed. One set of Mock and A6 cells were maintained in RPMI medium 
containing 1% FBS for 18 hrs to eliminate the affects of residual growth factors in serum. 
Subsequently, the migration potential of these cells were compared to the Mock and A6 
cells routinely cultured in RPMI containing 10% FBS. 
When the motility assay results were compared, the overall migratory potential of 
Mock and A6 cells cultured in RPMI and 1% FBS media for 18 hrs was found to be 15% 
less than the motility of cells cultured in complete growth media. Despite elimination of 
residual growth factor effects, A6 cells showed more than a 250% increase in migratory 
rate as compared with the Mock cells (Figure 4.26). The ability of A6 cells to retain their 
pro-migratory phenotype under serum deprived conditions suggested that CD9 mediated 
motility in CHO cells is a phenomenon that is independent of effects of growth factors in 
the serum.  This prompted us to investigate the role of integrins in CD9 mediated cell 
motility.  
Integrin α5β1 is expressed endogenously in CHO cells and has been shown to 
regulate cell adhesion and migration on FN (147, 201). Since CD9 also induces specific 
phenotypic changes on FN in CHO cells and because CD9 associates with α5β1, we 
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Figure 4.26 Effects of Serum on Mock and A6 Cell Migration 
 
Migration of Mock and A6 cells grown in 10% fetal bovine serum (FBS), 1% FBS. Cells 
were allowed to migrate for 3 hrs and cells were counted in 5 random high power fields 
(n=3). * represents p < 0.05 compared to the respective Mock cells. The error bars 
represent the standard deviation. 
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investigated the importance of integrin α5β1-FN binding in CD9 promoted haptotactic 
cell migration. Cook et al,1999 have previously shown that the α5β1 inhibitory antibody 
(PB1) reversed the characteristic spread phenotype induced by CD9 in CHO cells (173). 
We utilized a similar strategy to understand the importance of integrin α5β1 in CD9 
promoted motility. 
Monoclonal antibodies specific for integrin α5β1 (PB1) and subunit β1 (7E2) 
were developed and subsequently characterized in CHO cells (147).  PB1 has been shown 
to inhibit α5β1-mediated functions in CHO cells on FN (201). To test the contribution of 
α5β1 in CD9 promoted cell migration on FN, haptotactic motility experiments were 
performed using Mock and A6 cells pretreated with the α5β1 blocking mAb, PB1. As a 
negative control Mock and A6 cells treated with the isotype matched mAb (MOPC-21) 
were used. 
As shown in Figure 4.27, treatment of cells with the MOPC-21 did not 
significantly inhibit A6 cell migration. The data shown are the results from the highest 
concentration of MOPC-21 used in the motility experiments. Even at concentrations as 
high as 100 µg/ml, MOPC-21 did not inhibit CD9 promoted cell migration (p=1.00 as 
compared with the untreated control). However, treatment of A6 cells with 5 µg/ml of the 
PB1 antibody significantly inhibited (p=0.007 as compared with the mIgG control) CD9 
promoted migration on FN. At 5 µg/ml concentration of PB1 Mock cell migration was 
only moderately effected.  
Since integrin mediated functions are dependent on the activation state of integrin 
we next wanted to investigate whether CD9 directly modulates integrin β1 conformation. 
In cultured cells, integrins can be activated by treating cells with divalent cations such as 
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Figure 4.27 Effects of α5β1 Blocking Antibody (PB1) on A6 Cell Migration 
 
Mean cell migration of untreated A6 cells (-) and A6 cells treated with mouse IgG control 
(MIgG) or the α5β1 blocking antibody (PB1). * represents p < 0.05 as compared to the 
MIgG treated group (n=3). The error bars represent the standard deviation. 
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Mn2+ and Ca2+ or with ligand mimetic peptides (211-213). Integrins activated by several 
of these reagents expose newer epitopes known as the ligand induced binding sites 
(LIBS). LIBS can be specifically recognized by mAbs known as LIBS antibodies that 
have a characteristic high affinity binding to the active conformation of integrins. 
Several β1 specific LIBS antibodies have been generated to study its activation 
state. Most of these antibodies are generated against either mouse or human β1 integrin 
thus limiting their usage in other animal model systems. Since we intended to investigate 
β1 activation state in CHO cells, we initially screened various mouse specific LIBS 
antibodies to bind hamster β1 integrin. Among the antibodies screened, only 
B44antibody specifically recognized hamster β1 in its active conformation. B44 antibody 
was previously shown to recognize active conformation β1 integrin (213, 272). 
The RGDS sequence corresponds to a highly conserved region of the ECM ligand 
FN and has been shown to activate α5β1 complex. Therefore, experiments were 
performed where relative binding of B44 antibody to Mock and A6 cells was tested in the 
presence of ligand-mimetic RGDS peptide. This allowed us to directly compare the 
effects of CD9 expression on β1 conformation state. Mock and A6 cells were first treated 
with either RGDS or RGES (negative peptide control) and then allowed to bind the B44 
antibody. A positive signal from B44 binding was detected using a GAM-FITC 
secondary antibody. 
Our results indicate that treatment of cells with the negative control RGES peptide 
did not induce a significant activation of β1 integrin. Based on binding of B44 to RGES 
treated cells we observed that both Mock and A6 cells expressed similar levels of β1 
integrin on their surface. However, in the presence of integrin activating peptide RGDS, 
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both Mock and A6 cells had significantly higher binding of B44 antibody as compared to 
the respective RGES treated control group. 
In support of our hypothesis that CD9 can potentially influence the conformation 
of  β1, there was a significantly higher binding of B44 antibody in A6 cells (Figure 4.28) 
as compared to the Mock cells (n=5, p < 0.05). Although the above results clearly suggest 
that enhanced B44 binding is observed only in the presence of ligand-mimetic peptide 
RGDS, our findings do not address the mechanism by which CD9 can modulate 
conformation of β1. It is yet to be determined whether CD9 by virtue of physical 
association with β1 directly contributes to the stabilization of active conformer of β1.  
In summary, these data show that CD9 expressing cells retain their pro-migratory 
phenotype in the absence of a residual growth factor effect and suggest that CD9 
promoted migration is due to its influence on adhesion molecules rather than growth 
factor receptors. Since, anti-α5β1 antibody PB1 inhibited CD9 promoted migration, it 
can be concluded that α5β1 interactions with its ligand FN are essential for CD9 
promoted migration and that CD9 can serve to upregulate α5β1 mediated events. Our 
results emphasize an important regulatory role for CD9 in modulating integrin 
conformation.  
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Figure 4.28 FCM Analysis of B44 Antibody Binding to Mock and A6 Cells 
 
Results of quantitative Flow cytometry (FCM) experiments comparing relative binding of 
β1 conformation sensitive antibody (B44) to Mock and A6 cells in the presence of 
integrin ligand-mimetic peptide RGDS or the negative control peptide RGES. * indicates 
p < 0.05 between RGDS treated Mock and A6 cells. The error bars represent the standard 
deviation. 
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Chapter 5: Summary 
 
In the current study we investigated the mechanisms governing CD9 effects on 
cell migration. We examined the contribution of the signaling pathways, PI-3K, PKC, 
and MAPK that were previously shown to be important in regulating cell migration. CD9 
induced haptotactic cell migration on FN was inhibited by inhibitors of the PI-3K 
pathway but not by the inhibitors of PKC or MAPK pathway. Downregulation of PI-3K 
via dominant/negative PI-3K cDNA transfection also inhibited CD9 promoted haptotactic 
CHO cell migration. In support of these findings, both stable and transient expression of 
CD9 in CHO cells and RASM cells, respectively, induced enhanced phosphorylation of 
serine 473 on Akt in response to FN. PI-3K inhibitors abolished CD9 effects on Akt 
phosphorylation under these conditions demonstrating that Akt phosphorylation was 
reflective of PI-3K activity.  
On adhesion to FN, CD9-CHO cells exhibited enhanced tyrosine phosphorylation 
of protein in the 105-250 kDa molecular weight range which was identified as the 
signaling adaptor protein p130Cas. Subsequent examination revealed that total p130Cas 
protein were significantly higher in CD9-CHO cells compared to Mock control cells. The 
putative role of p130Cas in CD9 mediated cell migration was investigated via p130Cas 
specific siRNA mediated knockdown. Inhibition of p130Cas expression levels did not 
significantly affect haptotactic migration of CD9-CHO cells on FN. 
Using Brij-98 as the detergent to solubilize membrane proteins, we investigated 
the interactions of CD9 with β1 and β3 integrins by IP. In platelets, CD9 physically 
associated with the integrin GPIIb/IIIa and in cultured cells CD9 associated with the β1 
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integrin. In RASM cells, upon transient expression of CD9, integrin α5β1 was found in 
complex with CD9 and in MEF, endogenously expressed CD9 associated with α5β1.  
CD9 expressing CHO cells retained their promigratory phenotype after serum 
starvation demonstrating that CD9 effects on cell migration are predominately governed 
by cell adhesion mechanisms rather than those involving growth factor receptors.  The 
observation that the α5β1 blocking mAb, PB1 negated CD9 induced promigratory 
phenomenon provided further evidence that crosstalk between CD9 and α5β1 was 
required for CD9 promoted migratory activity in response to FN. In CHO cells, CD9 
expression significantly enhanced the binding of a conformation sensitive mAb to 
activated β1 in the presence of α5β1 activating peptide. These data indicated that CD9 
may stabilize the active conformation of integrin α5β1. 
The mechanism by which CD9 enhances PI-3K activity in cells still remains to be 
elucidated. Previous studies showed that CD9 immune complexes were demonstrated to 
contain PI-4K activity (20). However, an association of CD9 with PI-3K activity has not 
been reported. In our observation, immunoprecipitation of CD9 from CHO cells did not 
reveal the presence of the PI-3K subunits (data not shown) suggesting that there is no 
direct physical interaction of PI-3K with CD9. We hypothesize that CD9 mediated 
activation of integrin β1 is required for PI-3K activation. 
Both FAK and Src are tyrosine kinases that are known to be tyrosine 
phosphorylated upon integrin interaction with ECM leading to activation of PI-3K. Our 
preliminary finding suggest that phosphorylation of FAK on Y397 is not significantly 
altered upon CD9 expression (data not shown). Phosphorylation of FAK on Y397 residue 
was shown to be important in regulating PI-3K activity (266). Expression of CD9 also 
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did not significantly modify the phosphorylation state of Src and Src specific inhibitor 
SU6656 did not inhibit CD9 promoted cell migration (data not shown). These findings 
indicate that CD9 mediated activation of PI-3K does not require FAK and Src tyrosine 
kinases. In some model systems, Integrin β1 mediated activation of PI-3K was shown 
occur independent of FAK, Src activation (273).  
β1 transmembrane domain was shown to be important in the activation of PI-3K 
pathway and mutations in the β1 transmembrane were shown to adversely affect β1 
mediated signaling pathway. Specifically, β1 transmembrane domain mutations 
significantly altered p130Cas phosphorylation that was FAK independent but was 
inhibited by PI-3K inhibitor LY294002 (274). These results suggest that p130Cas may 
act downstream of PI-3K (274). Since only low efficiency siRNA transfection methods 
were used to downregulate p130Cas to study the effects on cell motility, the precise role 
of p130Cas in CD9 mediated migration and PI-3K activation further needs to be studied 
by more efficient methods for transfection.   
Cytoplasmic tail of β1 interacts with intracellular proteins such as talin and α-
actinin that link the integrin to the cytoskeleton (275). In migrating cells focal adhesion 
formation and turnover is determined by the extent of association between integrin and 
the cytoskeleton. Studying the roles of talin, α-actinin and characterizing the focal 
adhesion may further reveal the link between CD9 and PI-3K activation. The final 
common pathway leading to adhesive properties of cells such as cell motility and 
spreading involve changes in the cytoskeletal architecture. Since CD9 expressing cells 
exhibit characteristic adhesive phenotypes, we speculate that activation of PI-3K leads to 
changes in the cellular cytoskeleton.  
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Overwhelming evidence suggest that PI-3K is directly involved in regulating 
cytoskeletal architecture. Activation of PI-3K leads to generation phosphoinositides 
products that serve as docking sites for the PH domain containing proteins (276). 
Phosphoinositide products and protein interacting with them were shown to modulate 
guanine nucleotide exchange (GEF) activity of certain cytosolic proteins that regulate 
Rho family of GTPases such as Rac (277).Ahdeison of cells to matrix proteins such as 
FN was also shown to promote Rac activity (278). In motile cells, Rac has been shown to 
be important in lamellipodia formation at the leading edge of the cell (279). Signaling 
molecules such as Akt that are activated downstream of PI-3K were also shown to 
regulate Rac activity (280). Based on these evidences, we speculate CD9 expression 
activates Rho family of GTPases downstream of PI-3K activation leading to enhanced 
cell motility. Figure 5.1 summarizes the CD9 mediated intracellular events that lead to 
the activation of PI-3K pathway and cell motility. 
CD9 mediated cell motility has functional implications in several biologically 
important phenomenon such as vascular injury response. Our observations suggest that 
CD9 expression is altered VSMC after vascular injury and antibodies to CD9 modulate 
neointima formation in an injured vessel (Jennings et al, unpublished observations). 
These findings underscore an important regulatory role for CD9 in smooth muscle cells. 
In addition to vascular smooth muscle cells, CD9 is also expressed in endothelial cells. 
Since endothelial cells also participate in vascular injury response and because CD9 was 
shown to regulate endothelial cell migration we speculate that understanding the 
mechanism underlying CD9 mediated cell migration lay a foundation for the 
development of novel therapeutic strategies for cardiovascular diseases.  
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Figure 5.1 Summary of Events Leading to CD9 Mediated Cell Motility 
 
CD9 can upregulate integrin α5β1 leading to activation of PI-3K. The 
phosphoinositides product (PI 3,4,5 P3) generated regulate the activity of 
the Rho family of GTPase, Rac. Enhanced Rac activity in cells can lead to 
lamellipodia formation and enhanced cell motility. 
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